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SUMMARY 
The importance of NK cells in innate immunity as well as for the adaptive immune response has 
long been characterized. Accordingly, NK cell effector functions have been well studied. In 
contrast, little is known about NK cell developmental pathways and the transcriptional 
machinery behind. 
The transcription factor STAT5 is essential for regulating proliferation, differentiation and 
homeostasis of hematopoietic cells. This is also reflected by the fact that deletion of Stat5 in 
mice causes embryonic lethality. Conditional knock out studies using B and T cell specific Cre 
lines revealed an essential role for STAT5 in T and B lymphoid development. However, the lack of 
a NK cell restricted Cre line has precluded the investigation of STAT5 in NK cells. 
During my PhD study I have generated a transgenic mouse line that expresses the Cre 
recombinase specifically in NK cells. To do so, I used a BAC transgenic approach where the Cre 
recombinase was expressed under the control of the Ncr1iCre promoter. I tested the functionality 
and lineage specificity by crossing Ncr1iCre mice to the EGFPLSL reporter mouse line. I verified that 
Ncr1 dependent Cre recombination was restricted to the NK cell compartment. To exclude any 
toxic effects of the Cre recombinase expression per se in Ncr1iCre mice, I performed a 
comprehensive analysis of NK cell development and function. 
In order to investigate the role of STAT5 in NK cells, I crossed Stat5f/f mice to Ncr1iCre transgenic 
animals. Stat5f/f Ncr1iCre mice were largely devoid of NK cells in peripheral lymphoid organs. NK 
cell development was impaired in the bone marrow; NK cell maturation was blocked at the NK 
cell precursor stage. In vitro deletion of Stat5 in IL-2 expanded NK cells was incompatible with NK 
cell viability reflecting our in vivo data. To investigate the functional consequences of the Ncr1 
dependent deletion of Stat5, I performed in vivo studies and monitored NK cell mediated 
antitumor activity. Whereas NK cell mediated tumor surveillance in Stat5f/f Ncr1iCre mice was 
strongly impaired, CD8+ T cell dependent tumor control was undisturbed. Thus the results 
obtained from my PhD study demonstrate a cell intrinsic role for STAT5 in NK cell development 
and reveals that Ncr1 mice are a powerful novel tool to investigate NK cell development, biology 
and function. 
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ZUSAMMENFASSUNG 
Aus bisher publizierten Studien wissen wir, dass Natürliche Killer (NK) Zellen eine wichtige Rolle 
im angeborenen als auch im erworbenen Immunsystem spielen. Im Gegensatz zu den sehr gut 
charakterisierten Effektorfunktionen dieser Zellen ist nur wenig über die molekularen 
Mechanismen der NK Zell Entwicklung bekannt. Um das therapeutische Potential dieser Zellen 
nützen zu können ist es allerdings unumgänglich, diesen Vorgang besser verstehen zu lernen.  
Der Transkriptionsfaktor STAT5 ist essentiell für die Regulierung wichtiger zellulärer Funktionen 
wie Wachstum, Differenzierung und Homeostase. Das Fehlen dieses Gens führt zu embryonaler 
Letalität in Mäusen. Konditionelle Knockout Studien mit B und T Zell spezifischen Cre Mauslinien 
zeigen, dass STAT5 elementar für die Entwicklung dieser Zellen ist. In NK Zellen konnte die Rolle 
von STAT5 in vivo noch nicht erforscht werden, es gab bis dato keine NK Zell spezifische 
transgene Cre Maus Linie. 
Während meiner Doktorarbeit generierte ich eine Mauslinie, die es ermöglicht, die Wichtigkeit 
eines Zielproteins spezifisch in NK Zellen zu untersuchen. Dafür wurde die Cre Rekombinase 
unter der Kontrolle des Ncr1 Promotors exprimiert. Die Funktionalität und die Zellspezifität der 
Cre Rekombinase konnte in NK Zellen mithilfe einer GFP-STOPfloxSTOP Reportermauslinie 
gezeigt werden. Durch Verpaarung dieser Ncr1iCre Linie mit STAT5 gefloxten Mäusen konnte 
erstmals STAT5 spezifisch in NK Zellen deletiert werden. Das Fehlen von STAT5 in NK Zellen 
führte zu einer gestörten Reifung dieser Zellen im Knockenmark. Die Entwicklung zu reifen NK 
Zellen war blockiert und es kam zu einer Anhäufung von unreifen Vorläuferzellen. In peripheren 
lymphoiden Geweben waren kaum reife NK Zellen zu detektieren. Die in vitro Deletion von Stat5 
in NK Zellen bestätigte meine in vivo Ergebnisse. Um die funktionalen Konsequenzen dieser 
Deletion zu studieren, führte ich weitere in vivo Studien durch, wobei ich die NK-Zell vermittelte 
Tumorüberwachung studierte. Das Fehlen von STAT5 in NK Zellen führte zu einer stark 
verringerten Beseitigung von Tumorzellen durch NK Zellen, die Tumorüberwachung des 
angeborenen Immunsystems war nicht beeinträchtigt. 
Die Resultate meiner Doktorarbeit zeigten eine zellintrinsische Rolle von STAT5 für die NK Zell 
Entwicklung und demonstrierten, dass die hier generierte Ncr1 Mauslinie zukünftig sehr hilfreich 
sein wird, um NK Zell spezifische Funktionen zu studieren. 
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1 
INTRODUCTION 
1.1 Natural killer cells 
Natural killer (NK) cells represent a lymphoid subset of immune cells that principally mediates 
innate immunity but additionally fulfills important roles in interacting with the adaptive immune 
response thereby defining immune responses (1). 
NK cells attracted the attention of immunologists some thirty years ago by their ability to 
spontaneously lyse certain tumor cells in vitro without previous sensitization and so the term 
“Natural Killer” was coined by Eva Klein in 1975 (2). In 1984, Klas Kärre formulated the “missing 
self” hypothesis, where he proposed that NK cell activation is controlled by inhibitory receptors 
specific for self molecules called major histocompatibility complex (MHC) class I. His idea was a 
milestone in understanding how NK cells discriminate between self and aberrant cells (3, 4). The 
initial view has undergone some modifications and nowadays it is known that target cell 
recognition and NK cell activation is regulated by multiple germ-line encoded activating as well 
as inhibitory receptors with a delicate balance of positive and negative signals (5). With this 
heterogeneous arsenal of receptors, NK cells are not only capable of recognizing and eliminating 
tumor cells but also cells infected by certain viruses or parasites (6-8). Moreover, NK cells 
secrete a wide range of cytokines and chemokines such as interferon (IFN)-γ, tumor necrosis 
factor (TNF)-α, interleukin (IL)-13 and RANTES, thereby orchestrating the interplay of the innate 
and the adaptive immune system (9). Given this important attributes, most reports in the last 
decade have concentrated on unraveling the mechanism of target cell recognition and signaling 
pathways leading to NK cell effector function. In contrast, molecular pathways guiding NK cell 
development remain largely unknown. Nevertheless, a detailed understanding how NK cells 
develop is essential to develop the therapeutic potential of NK cells. 
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1.2 NK cell development and differentiation 
In adult mice, NK cell development takes mainly place in the bone marrow (10, 11) and 
progresses through three major stages defined by the expression of NK cell specific surface 
markers (12, 13). 
Committed NK cell precursors (NKPs) originate from multipotent hematopoietic cells and 
constitute the first developmental stage of NK cell development. NKPs express the common ß 
chain of the IL-2 and IL-15 receptors (CD122) and lack surface proteins associated with mature 
hematopoietic cells (referred to as lineage negative or Lin-). Moreover, NKPs are negative for 
known NK cell markers such NKRP1C (CD161c) recognized by NK1.1 antibodies in C57Bl/6 and 
C57Bl/10 mouse strains, the α2 integrin CD49b (defined by the DX5 mAb clone) and Ly49 
receptors. However, this subset seems to be heterogeneous in that some cells express NKG2D 
and 2B4 and others not (14). Therefore, some reports suggest that true NKPs might be NKG2D 
and 2B4 positive (only 10 % of NKPs give rise to NK cells in vitro) (12, 15). Nevertheless, the 
function of NKG2D on this immature cell type remains to be determined since NKG2D is 
normally associated with cytotoxicity potential. 
As NKPs further differentiate into immature (i) NK cells, they progressively acquire NK1.1 and the 
natural cytotoxicity receptor (NCR) 1, an activatory receptor expressed constitutively and 
exclusively by NK cells (16). NCR1 is involved in the recognition and lysis of various tumor (17, 
18) and virus infected cells (19, 20). The ligands of this receptor are not well characterized but 
heparan-sulfate proteoglycans might be involved (21). Furthermore, receptors specific for MHC 
class I molecules like CD94 in combination with NKG2A/C/E and certain Ly49 receptors are 
expressed and tested in a poorly understood process called “NK cell education” to become self 
tolerant (22). Ly49 receptors are expressed in a monoallelic and variegated manner due to 
epigenetic regulation and to the use of a bidirectional switch promoter resulting in a stable 
expression of individual (up to five) Ly49 genes in only a subset of NK cells (23-25). These iNK 
cells are not cytotoxic in vitro towards the lymphoma cell line YAC-1 and do not secrete IFNγ 
(12). 
As differentiation proceeds, the cells subsequently express CD49b and acquire their cytolytic 
potential and cytokine producing capacity. Upregulation of CD49b defines the mature (m) NK 
cell stage. This population is expanded in the bone marrow and further maturation is associated 
with the expression of two additional markers: CD11b (Mac1) and CD43 (sialophorin). Indeed, 
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increased expression of CD11b as well as CD43 correlates with functional maturity (26). The cells 
are now fully responsive, emigrate from the bone marrow to peripheral sites and recirculate 
through the blood. However, not only mNKs have access to the periphery; recent studies suggest 
that also NKPs and iNKs are found at peripheral sites such as the lymph nodes in human and the 
liver (26, 27) (Fig.1). Liver iNKs, for example, are CD11bloCD49blo, express CD94-NKG2 and lack 
Ly49 receptors. They are poor IFNγ producer but express TRAIL, a TNF family member, capable 
of inducing apoptosis in target cells via death domains containing TRAIL receptors. Takeda et al 
have shown that TRAIL+ liver iNKs can develop into TRAIL- mNK cells after adoptive transfer 
experiments in vivo (28). These observations reinforce the idea that distinct tissue sites may 
support NK cell differentiation.  
In the thymus, a population of NK cells has been described that display high levels of CD127 (the 
IL-7 receptor α-chain), low levels of CD11b and lack Ly49 receptors (29). Moreover, they show 
reduced lytic capacity but secrete abundant pro-inflammatory cytokines such as IFNγ, TNF and 
GM-CSF when re-stimulated in vitro. Thymic NK (tNK) cells preferentially home to the lymph 
nodes and fail to develop in athymic (Foxn1-/-) mice but are barely present in the spleen, bone 
marrow and liver. Based on their lower cytotoxicity but increased capacity to produce cytokines, 
it has been suggested that they might play an important role in achieving immune regulatory 
functions at the thymus and the lymph nodes (30). Unlike conventional NK cells, development of 
tNK cells requires IL-7 and the transcription factor GATA3. A multipotent early thymic progenitor 
(ETP) has been described in the liver that compromises the most immature T cell progenitor and 
is able to differentiate into T cells as well as NK cells (31, 32). This finding is consistent with the 
idea that tNK cells develop in situ from a hematopoietic precursor which seed the thymus and 
differentiate by a developmental program distinct from that used in the bone marrow (1). 
Alternatively, NK cell precursors from the bone marrow might emigrate to the thymus where 
they receive tissue specific signals that induce their altered phenotype. 
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Figure 1. Multiple sites for NK cell development. (Taken from Di Santo 2007 in Nat. Rev. Immunol. (1)) 
Three distinct stages can be distinguished in the life of a NK cell. At the first stage, NKPs are generated 
from hematopoietic precursors and ELPs. Commited NKPs give rise to iNK cells at the second stage. This 
process involves the acquisition and fine tuning of molecules needed for target cell recognition. At the last 
stage, mNK cells acquire full functional competence. NK cell differentiation takes mainly place in the bone 
marrow but it occurs also at distinct peripheral tissue sites. It has been suggested that, in addition to mNK 
cells, NKPs and iNKs may recirculate between the different tissue sites. HSC: hematopietic stem cell. ELP: 
early lymphoid precursor. NKP: NK cell precursor. iNK: immature NK cell. mNK: mature NK cell. 
 
Diversity among NK cell 
As the distinct tissue sites of differentiation already implicate, NK cells are not homogenous and 
a large body of evidence exists for specialist NK cell subsets. Different cell surface markers have 
been used to classify phenotypically and functionally distinct NK cell subsets. As described 
above, hepatic iNK cells are TRAIL+ and tNK cells express CD127. But not only developmental 
origins contribute to NK cell diversity. Mature NK cells can be distinguished on the basis of their 
CD11b and CD27 expression. CD11bloCD27hi NK cells are primarily found in the bone marrow and 
show a high rate of homeostatic proliferation. CD11hiCD27hi cells are present in the spleen, liver 
and lymph nodes and display potent effector function. In contrast, CD11bhiCD27lo cells are poorly 
cytotoxic and may represent senescent cells (26, 33). It has been proposed that NK cell 
maturation follows a 4-stage process that starts at a CD11blowCD27lo stage and proceed through 
CD11bloCd27hi  Cd11bhiCD27hi  CD11bhiCD27lo stages (34). Furthermore, during pregnancy, 
uterine NK (uNK) cells secrete vascular endothelial growth factor (VEGF) and placental growth 
factor (PLGF) at significantly higher levels than their peripheral blood counterparts thereby 
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supporting the remodeling of the arterial systems that may encourage successful implantation 
and placental development (35, 36). Recently, two different subsets of NK cells in the uterus 
have been identified: CD3-CD122+ cells that are indistinguishable from peripheral NK cells and 
NCR1+NK1.1-DX5-NKG2D+ cells that express a unique receptor repertoire (37). However, the 
origin and the detailed function of uNK cells remains elusive. 
More recently, a novel subset of NK cells secreting IL-22 (NK22) has been identified in the 
mucosa-associated lymphoid tissue (MALT)(38, 39). IL-22 belongs to the family of IL-10 related 
cytokines and protects the epithelial cell barrier against mucosal pathogens through the 
upregulation of anti-apoptotic and bactericidal proteins (40-42). Various studies have shown 
that IL-22 is an important mediator to protect against inflammatory diseases such as hepatitis, 
autoimmune myocarditis and inflammatory bowel disease (43-46). NK22 cells increase IL-22 
production upon IL-23 stimulation, display a CD3-NKp46+CD127+ phenotype and variably express 
NK1.1 (30). NK22 express a transcription factor called RORγt that is known to be required for the 
development of lymphoid tissue inducer (LTi) cells (47). Mice lacking RORγt display significant 
decreased levels of NK22 cells and fail to develop lymph nodes and cryptopatches (48-50). It has 
been shown that Rag2-/- mice infected with C.rodentium (which lack IL-22 produced from T cells) 
and depleted of NK cells showed accelerated mortality (48). Therefore, the idea arose that NK22 
cell precursor may reside in secondary lymphoid tissues and could differentiate upon microbial-
driven inflammation (30). Interestingly, a major subset of NK22 cells are NK1.1- and do not 
require IL-15, unlike classical NK cells. This phenotype closely resembles LTi cells. LTi cells are 
found in the gut, depend on the transcription factor ID2 for their development and are 
mediators in the formation of gut-associated Peyer´s patches and other secondary lymphoid 
organs. In contrast, a minor subset of NK22 cells is NK1.1+ and IL-15 dependent. It is currently 
under debate whether LTi-like and NK22 cells originate from the conventional NK cell lineage 
and represent two consecutive developmental stages or, alternatively, whether they derive from 
one precursor through different pathways (30).  
One of the most unexpected recent findings is related to the discovery that some mNK cells can 
be functionally divided into a memory like NK cell subset. As mentioned above, NK cells have 
traditionally been considered as effector cells of the innate immunity. This is supported by the 
fact that NK cells (in contrast to T and B cells which belong to the adaptive immunity) do not 
express recombination-activating gene (RAG) proteins necessary for somatic rearrangement of 
V(D)J gene segments in order to achieve an almost unlimited number of highly diverse antigen 
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specific receptors. Another cardinal feature of adaptive immune cells is their immunological 
memory. However, it has recently been shown that NK cells might cross over this traditional 
boundary with their potential capacity to learn and remember. This subtype of 
KLRGIhiCD43hiCD27- NK cells secretes more IFNγ compared to naïve mNKs and has a potent 
cytolytic capacity (14). O’Leary et al have shown in a provocative study that NK cells can mediate 
a hapten specific contact hypersensitivity (CHS) response, which is traditionally thought to be a 
classical delayed type hypersensitivity response conducted by T cells (51). Moreover, the 
adoptive transfer of NK cells from hapten sensitized mice into naïve animals led to a CHS 
reaction when recipients were challenged with the original hapten. The CHS response was 
specifically seen after the transfer of Ly49C/I+ liver NK cells. Another study has demonstrated 
that NK cells activated via the cytokines IL-12 and IL-18 display an NK cell intrinsic, enhanced 
IFNγ production upon re-stimulation (52). This effect persists for at least three weeks, which is 
rather long considered that the half life of an NK cell lies between one week and 17 days (53, 
54). Additionally, it has been shown that Ly49H+ NK cells specifically expand after MCMV 
infection (55), persist at least two month thereafter and provide an even better protection 
against MCMV when transferred into newborn mice (56). Although no definitive phenotypic 
markers for NK cell memory were found, mature subsets of NK cells may exist that have 
previously been activated by antigens and remain functionally distinct from other mature 
subsets (30, 57). 
 
1.3 Cytokines and signaling pathways required for NK cell development 
Cytokines such as IL-2, IL-4, IL-7, IL-15 and IL-21 are soluble proteins that regulate proliferation, 
development and homeostasis of lymphocytes. These interleukins belong to the type I cytokine 
family and signal through receptors that all contain the common cytokine receptor γ chain (γc). 
The receptors for IL-4, IL-7, IL-9 and IL-21 are composed of two polypeptide chains whereas the 
IL-2 receptor (IL-2R) and the IL-15R are trimeric complexes that have unique α chains responsible 
for high affinity binding of its cytokine but share a common β chain (IL-2Rβ, CD122) (Fig2). Ligand 
binding results in the activation of the janus activated kinase (JAK)-signal transducer and 
activator of transcription (STAT) signaling cascade and other signaling pathways (58). 
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Figure 2. Cytokine receptors regulating proliferation, differentiation and homeostasis of lymphoid cells. 
(Taken from Spolski 2005 in Nat. Rev. Immunol. (58)) 
These cytokine receptors are composed of either two (IL-4R, IL-21R, IL-7R, IL-9R) or three polypeptide 
chains (IL-2R, IL-15R). All of these receptors share a common cytokine receptor γ chain (γc). Each of these 
receptors harbors a unique component, for example the IL-2R contains a unique IL-2Rα chain and the IL-
4R contains a unique IL-4R subunit. In addition, the IL-2R and the IL-15R share a common β subunit called 
IL-2/IL15 β (IL-2Rβ chain, CD122). Mutations in the γc chain lead to a severe disease called X linked severe 
combined immunodeficiency (XSCID). These type I cytokine receptors activate different signaling cascades 
such as the JAK-STAT pathway. JAK: janus activated kinase. STAT: signal transducer and activator of 
transcription  
 
The IL-2R is expressed on NK cells ells but also on several other immune cells such as T and B 
lymphocytes, neutrophils and monocytes and is produced by a subpopulation of activated CD4+ 
T cells. IL-2 has been described as T cell growth factor, promotes differentiation of T and B cells, 
plays a key role in activation induced T cell death and is now considered as a major regulator of T 
cell responses (59). IL-15 was initially identified through its capacity to stimulate proliferation of 
an IL-2 dependent cell line in the presence of anti-IL-2 antibodies (60, 61). The existing functional 
similarities can be in part explained because of the shared IL-2/IL-15Rβ and γc chains, (62, 63). 
However, a series of later studies have demonstrated that IL-2 and IL-15 exert quite different 
functions in the immune system and that IL-15 regulates a much broader spectrum of biological 
processes. This is also reflected by the fact that IL-15 is produced by a large variety of cell types 
including monocytes, macrophages, DCs, fibroblasts, epithelial cells of various origins and 
epidermal skin cells, among others (64). 
 
Roles of IL-2 and IL-15 in NK cell biology 
Studies have shown that IL-2 administration to bone marrow cultures leads to NK cell 
differentiation in vitro and allows NK cell expansion (59). However, NK cells are present in IL-2-/- 
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mice (65), even thought the NK cell activity was markedly reduced (66). In contrast, IL15-/- mice 
are severely deficient of peripheral NK1.1+ cells (67). IL15Rα-/- mice display a 3.5 fold reduction of 
CD3-DX5+ splenic NK cells and whole splenocytes show a severely reduced cytolytic capacity 
which was attributed to the NK cell compartment (68). Treatment of IL15-/- mice with IL-15 leads 
to increased NK cell numbers and induces NK cell activity (67, 68). Mice with a targeted deletion 
of the IL-2/IL-15Rβ chain or γc are devoid of peripheral NK cells (69-71). In contrast, IL-7 and IL-4 
appears to be neglectable for in NK cell development; IL7-/- mice have increased NK cell levels 
(15, 72) and IL-4 deficient mice only exhibit a slight reduction of splenic NK cells (15). These 
studies clearly define IL-15 as the main cytokine regulating NK cell development. Interestingly, 
IL-15 does not determine NK cell lineage commitment as IL-15 dependent signals are not 
required for the development of NKPs (15). However, the exact role of IL-15 in later stages of NK 
cell differentiation, proliferation and maintenance has not been clearly established, although a 
role for the survival of NK cells has been proposed (73, 74). The few NK cells that develop in the 
absence of IL-15 exhibit differences in the Ly49 receptor repertoire and display reduced CD11b 
levels indicating a more immature phenotype. Residual NK cells in a Rag2-/- IL15-/- mouse model 
are capable of cytolysis and IFNγ production although to a lesser extent (15). These findings 
indicate that IL-15 is the main cytokine involved in NK cell development, survival and expansion 
but is less essential for NK cell effector function. 
One interesting attribute of the IL-15/IL15R signaling complex was recently discovered. Despite 
conventional soluble cytokine delivery, it has been proposed that intracellular IL-15 binds to a 
high affinity IL-15 binding protein (e.g. IL15Rα in the endoplasmatic reticulum (ER)) that is 
shuttled to the cell surface where it activates IL-15 signaling components on neighboring cells 
through a cell-cell interaction (75). This transpresentation extend IL-15 actions from autocrine or 
juxtacrine signaling to paracrine or endocrine signaling (64) and it allows a more direct and 
controlled delivery to responsive cells. 
 
The JAK-STAT signaling pathway 
As discussed above, cytokines are secreted proteins that mediate intercellular communication 
thereby regulating important biological functions such as development, proliferation and 
homeostasis. The binding of a cytokine to its respective receptor leads to the activation of 
various signaling cascades including the JAK-STAT pathway. In the canonical mode of the JAK-
STAT signaling pathway, cytokine binding induces oligomerization of receptor subunits. 
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Subsequently, the JAK kinases, which are non covalently bound to the receptor, are brought into 
close proximity, allowing transphosphorylation on tyrosine residues thereby releasing their 
intrinsic catalytic activity. JAKs then phosphorylate tyrosine moieties in the cytoplasmic region of 
the clustered receptors. These regions are recognized by Src homology-2 (SH2) domains of 
monomeric STAT proteins, which become attached to the receptors. The STAT proteins are then 
phosphorylated by JAKs, dimerize via their SH2 domains, dissociate from the receptor and 
translocate to the nucleus where they activate gene transcription (Fig.3). 
 
 
Figure 3. The canonical JAK-STAT signaling pathway. (Taken from Levy 2002 in Nat. Rev. Mol. Cell Biol.) 
(76) 
Following ligand binding to its cognate receptor, receptor associated JAKs are activated. Specific tyrosine 
moieties on the receptor are subsequentially phosphorylated by JAKs thereby creating SH2 docking sites 
for monomeric STAT proteins. STATs are tyrosinphosphorylated (around residue 700 of their amino acid 
sequence) by JAKs, dimerize via their SH2 domains, dissociate from the receptor and translocate as dimers 
into the nucleus where they bind to gene promoters and activate transcription. 
 
A non canonical JAK-STAT pathway has been originally identified in Drosophila but recent 
findings indicate its occurrence also in mammals. It has been shown that a portion of the 
unphosphorylated STAT pool is located in the nucleus on heterochromatin associated with 
heterochromatin protein (HP) 1. Upon phosphorylation, STAT dissociates from heterochromatin, 
which in turn leads to the displacement of HP1 and to heterochromatin destabilization (77). It 
has been shown that JAK-STAT activation triggers major histocompatibility complex (MHC) 
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remodeling leading to chromosomal decondensation before transcriptional activation (78). 
Another study describes IFNγ chromatin remodeling upon JAK-STAT activation during T helper 
cell differentiation (79). Unphosphorylated STAT proteins have been reported in the nucleus, 
however, their subnuclear localization relative to heterochromatin has not been clarified yet (80-
83). Furthermore, it has been shown that unphosphorylated STATs are constantly shuttling 
between the cytoplasm and the nucleus (81, 82) and it has been demonstrated that 
unphosphorylated STAT proteins influences gene transcription by mechanism different from 
those used by phosphorylated STATs (84). Since JAK nuclear translocation has previously been 
reported (85) it remains elusive whether JAKs enter the nucleus to phosphorylate STAT proteins 
or, whether the redistribution of unphosphorylated nuclear STAT proteins follows from a 
changed equilibrium between nuclear and cytoplasmic (or phosphorylated and 
unphosphorylated) STATs due to JAK activation (77). 
 
Characteristic features of JAKs and STATs 
As described previously, JAKs are tyrosine kinases that are preassociated with membrane bound 
cytokine receptors as most of these receptors do not posses any kinase activity. Until now, four 
mammalian JAKs have been identified: JAK1, JAK2, JAK3 and Tyk2. Each JAK molecule contains a 
conserved kinase domain and a catalytically inactive pseudokinase domain (therefore the name 
janus kinase from the roman two-faced god, it refers to the idea that JAKS have two-faces 
consisting of the kinase and pseudokinase domains). The pseudokinase is assumed to regulate 
the kinase domain. The mammalian STAT family has seven members: STAT1, STAT2, STAT3, 
STAT4, STAT5A and STAT5B and STAT6. STATs are highly homologous in several regions including 
a SH2 domain involved in activation and dimerization of STAT molecules, a DNA binding domain, 
and a transactivation domain located at the C-terminus. The N-terminus is thought to be 
required for the regulation of STAT activity, such as tyrosine phosphorylation and tetramer 
formation (Fig.4).  
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Figure 4. Schematic domain structure of JAKS and STATs. (Taken from Shuai 2003 in Nat. Rev. Immunol. 
(86)) 
The domains JH1-JH7 are based on sequence similarity of the four identified JAKS. The JH1 is a functional 
catalytic domain with two tyrosine residues which are phosphorylated upon ligand binding. 
Phosphorylation results in conformational changes that facilitate substrate binding. JH2 is the 
pseudokinase domain probably involved in the regulation of the JAK activity and it might be a potential 
docking site for STATs. The domain JH3 shares homology with SH2 and JH4-JH7 is known as FERM domains 
necessary for localizing the protein to the plasma membrane. STATs contain a transactivation domain 
(TAD) regulating transcription at their C-terminus and alternatively spliced isoforms of STAT1, STAT3 and 
STAT4 lacking this domain display attenuated transcriptional activity. Serine phosphorylation promotes 
and enhances gene expression of selected gens and TAD phosphorylation is involved in regulation and 
crosstalk of different receptors by binding of other transcription factors and coactivators. The activation of 
STATs can also be regulated by other protein modifications such as methylation (MET), sumoylation 
(SUMO), ISGylation (ISG15) and acetylation (Ace). 
 
Genetic knockout studies have shown that the loss of JAK kinases leads to severe defects and in 
the case of JAK2 to embryonic lethality. The JAK-STAT signaling pathway must therefore be 
tightly regulated. A great deal of work has revealed that JAK-STAT signaling can be regulated at 
many stages by different mechanism (86). SOCS proteins are one of the key regulators, normally 
expressed at low levels in unstimulated cells, which become rapidly induced upon cytokine 
activation. SOCS proteins are capable of binding directly to tyrosine phosphorylated JAKs leading 
to inhibition of JAK activity (87-89). Another SOCS member called CIS binds directly to receptor 
docking sites of STATs thereby competing with STAT proteins. Finally, SOCS proteins are involved 
in the ubiquitin proteasome pathway mediating the degradation of JAKS and other signaling 
proteins. Other key regulators are various protein tyrosine phosphatases (PTPs) involved in the 
negative regulation of the JAK-STAT pathway in the cytoplasm as well as in the nucleus (86). 
Distinct protein modifications (ubiquitylation and ISGylation) and the cross talk between 
different JAK-STAT pathways and other signaling cascades provide additional levels of regulation. 
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Given the fact that approximately more than 25 cytokines signal via a limited panel of JAKs and 
STATs (and via other signaling pathways leading e.g. to the activation of MAPKs not discussed 
here), one major unresolved question is how cytokines achieve their specificity. Cytokine 
signaling could theoretically be made specific by each cytokine binding to its own specific 
receptor. It turn more and more out, however, that cytokine receptors share particular receptor 
chains such as the IL2/IL5 β chain or the γc, which would limit specificity. Genetic studies have 
shown that different cells express distinct receptor combinations. Therefore, a single cell may 
integrate signals from various receptors and different classes of receptors use preferentially a 
certain JAK combination (65). Hematopoietic cell development and proliferation is for example 
mediated by cytokine receptors using JAK2, γc receptors use JAK1 and JAK3 whereas other 
receptors use only JAK1 (Fig. 5). 
 
 
Figure 5. Different combinations of JAKs are used by distinct cytokines. (Taken from Murray 2007 in J 
Immunol. (90)) 
Shown are various JAK combinations responding to different cytokines. Distinct cell types and tissues 
express different receptor combinations unique to the microenvironment. Therefore, a single cell might 
integrate signals from diverse cytokine receptors. The cytokines IL-2 and IL-15 signal through JAK1 and 
JAK3 by using the γc chain, specificity is mainly reached by the unique alpha chain of the IL2 and IL15 
cytokine receptor. Subsequentially, STAT proteins are activated and induce a particular set of target genes. 
 
The biology of STAT5 
STAT5 consists of two highly homologous isoforms, STAT5A and STAT5B, encoded by two 
juxtaposed genes. Their transcriptional starts are within 10kb of each other located on 
chromosome 11 in mice (91). STAT5A and STAT5B cannot entirely compensate for each other 
and cell preferential transcriptional patterns have emerged (92). STAT5A-/- mice display impaired 
mammary development and differentiation during pregnancy (93) and T cells from these mice 
show decreased proliferation secondary to diminished IL-2Rα chain expression (94). In contrast, 
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STAT5B-/- mice resulted in stunted body growth (95) and decreased NK cell numbers (96). The 
first attempt to create a STAT5A/B knock out mouse resulted in hypomorphic N-terminally 
truncated STAT5A and STAT5B proteins (referred to as STAT5ΔN) with different expression levels 
depending on the tissue type (97). Immunological defects of these mice were not as severe as 
had been expected from mutations resulting in the abortion of the JAK-STAT signaling pathway 
induced by a number of cytokines. It turned out that residual STAT5ΔN proteins are still able to 
form dimers (but not tetramers), bind DNA and activate transcription of some target genes even 
without cytokine stimulation. The development of T and B cells are only minimally affected (98, 
99), although peripheral T cells fail to proliferate in response to cytokine signaling and regulatory 
T cells are diminished in STAT5ΔN/ΔN (100). The interpretation of the obtained phenotype is 
complex and requires revalidation in a mouse model completely devoid of STAT5 proteins. To 
solve this problem, conditional mice that carry a 110 kb Stat5a/b locus flanked by loxP sites have 
been generated permitting Cre recombinase based deletion of both STAT5 genes (101). Mice 
doubly deficient in STAT5A/B proteins are infertile and ≥95 % of the pups die perinatal. 
Stat5A and STA5B proteins have essential and largely redundant roles in the development of 
immune cells and in orchestrating immunoregulation downstream of the IL-2, IL-7 and IL-15 
cytokine receptor. STAT5A/B deficiency has a severe impact on the development of B and T cells 
(102-104). The conditional deletion of STAT5A/B in the T cell lineage results in the loss of 
cytotoxic T cells, impaired development of regulatory T cells and enhanced production of T 
helper 17 cells (105, 106). 
Moreover, a variety of solid tumors, leukemias, and myeloproliferative disorders (MPDs) are 
characterized by constitutively active STAT5 proteins providing a survival and proliferation 
advantage for abnormal cells. STAT5 has been implicated in BCR-ABL induced chronic myeloid 
leukemia (CML) and in blast cells from patients with acute myeloid leukemia and acute lymphoid 
leukemia (91). It has been shown that STAT5 is absolutely required for the initial transformation 
and maintenance of BCR-ABL induced leukemia (107). Taken these findings together, STAT5 may 
represents a promising and attractive therapeutic target. 
 
Transcription circuitry of the NK cell lineage 
In contrast to the growing body of literature on the mechanisms controlling NK cell cytotoxicity, 
target cell recognition and proinflammatory cytokine production, much less is known about NK 
cell lineage specification and commitment. Several transcription factors have been characterized 
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to play distinct roles in developing NK cells, particularly from the iNK cell stage on, these include 
ETS-1 (108), PU.1 (109), ID2 (110), GATA-3 (111), and MEF (112). Very recently two research 
groups identified E4BP4 as critical transcription factor required for early NK cell development 
(113). 
The ETs-1 family of transcription factors is composed of nearly 30 proteins that have a related 
winged helix-turn-helix DNA binding domain. It has been shown that Ets-1-/- mice display a 3-fold 
reduction in NK cell numbers and have a defective cytolyotic and cytokine production capacity 
(108). ETs-1 regulates CD122 in transient transfection assays implicating that this transcription 
factor promotes IL-15 responsiveness. IL-15 induces ERK-dependent phosphorylation of ETs-1, 
which in turn increases ETs-1 protein levels and transcriptional activation. Therefore, ETs-1 
might be part of a positive feedback loop (114-116). In NKPs, ETs-1 mRNA is increased compared 
to CLPs and it has been speculated that ETs-1 might function in the initial activation of CD122 
expression (23). 
PU.1, another ETs family member, is involved in the development of multipotent lymphoid 
progenitors and is indispensable for B lymphocyte development (117). The deletion of PU.1 in 
mice leads to embryonic lethality. Fetal liver transplantation into Rag2-/- γc
-/- mice showed that 
PU.1 is not required for mNK cells, even though the number of NKPs and mNKs is reduced (109). 
It remains elusive whether the diminished number of NKPs is due to an impaired development of 
multipotent lymphoid progenitors or whether PU.1 functions directly in NK cell lineage 
specification. Colucci et al further have shown that PU.1-/- mNK cells fail to be activated by IL-2 or 
IL-12, display an altered Ly49 receptor repertoire and show reduced levels of IL-7Rα and c-kit 
indicating that PU.1 has additional roles in NK cell biology. Interestingly, these cells lyse target 
cells as efficiently as the wildtype control in vitro (109). PU.1 deficient mNK cells display 
increased ETs-1 mRNA implicating a compensating role for the loss of PU.1. MEF belongs to the 
ETs-family of proteins as well and mNK cells deficient of MEF have impaired effector functions 
(112).  
T-BET and eomesodermin (EOMES) are T-box (TCACACCT) binding proteins implicated in NK cell 
development. T-BET is expressed in various immune cells and is known to be required for CD4+ T 
cell development. Mature NK cells from mice deficient for T-BET express c-kit and αv integrin 
indicating an immature status. However, they also express high levels of CD69 and proliferate 
extensively suggesting a hyperactivated phenotype (118). T-BET and EOMES directly regulate the 
genes of IFNγ and CD122 and this combined function of EOMES and T-BET on the CD122 
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promoter regulates IL-15 responsiveness. It has been shown that this two transcription factors 
are necessary for the development of CD122hi T-cells (119). Therefore, EOMES and T-BET might 
cooperate to regulate CD122 during NK cell development. Interestingly, heterozygosity of 
EOMES does neither effect NK cell development nor NK cell function. However, the additional 
loss of one or both alleles of T-BET revealed a synergistic loss of mature NK cells (119). It remains 
elusive, whether this T-box binding proteins are needed for specification of the NK cell lineage 
from a multipotent progenitor, or whether their functions lie in regulating CD122 expression and 
responsiveness to IL-15. 
GATA3 has been shown to be essential for thymic NK cells (29). In contrast, GATA3 is expressed 
only at low levels in bone marrow NK cells and is needed for the development of mNK cells 
expressing CD43 and CD11b. Mature NK cells lacking GATA3 fail to home to the liver and are 
poor IFNγ producer but capable of target cell lysis (111). Interestingly, these NK cells show 
reduced levels of T-BET expression indicating a T-BET upstream function in the regulation of IFNγ 
transcription. 
The inhibitor of differentiation (Id) proteins belong to the helix-loop-helix (HLH) family of 
transcription factors. Some members act as positive regulators, where they bind DNA either as 
homo- or heterodimers and regulate transcription. In contrast, negatively acting factors lack a 
DNA binding domain and associate with other members of the Id family, thereby preventing 
them from binding DNA or forming active heterodimers (120). ID2 is necessary for NKP 
development in the fetal thymus and for mNKs in the spleen (121, 122). This transcription factor 
is further expressed in bone marrow NKPs but, interestingly, is dispensable for the development 
of committed NKPs (110). However, Id2-/- bone marrow NKPs showed increased ID3 levels, which 
might compensate for the loss of ID2. Furthermore, Boos and colleagues demonstrated a 
requirement for ID2 at the mNK cell stage in the bone marrow. In these cells, ID3 expression is 
markedly decreased (110). Id proteins are antagonists of E-box (CANNTG) binding (E) protein 
transcription factors and it has been suggested that the impaired NK cell development in the 
bone marrow is due to excessive E protein activity since loss of the E family member E2A 
restores mNK cells in Id2-/- bone marrow (110). However, these mNK cells do not express CD11b 
and Id2-/- E2A-/- mNK cells fail to accumulate in the spleen or peripheral blood indicating that E2A 
may not be the only E protein target of ID2 in mNK cells (110). In summary, Id2-/- mice have a 90 
% reduction of mNK cells in the spleen but have no fewer NKPs or iNKs in the bone marrow. This 
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developmental block is later than that in the IL15-/- mice, which display a much less iNK cell 
production. 
Very recently, the E4-binding protein 4 (E4BP4) has been identified as the first transcription 
factor that is critically required for NK cell development. E4BP4 is a member of the basic 
region/leucine zipper (bZIP) transcription factor superfamily and plays an important role in IL-3 
dependent pro-B cell survival (123). E4bp4-/- mice show no gross abnormalities and have an 
undisturbed hematopoietic and lymphoid profile with the exception of NK cells. NKPs are normal 
but the levels of iNK cells and mNK cells are considerable lower. Moreover, CD3-NKp46+NK1.1+ 
NK cells are conspicuously absent from the bone marrow, spleen and blood (113) Gascoyne et al 
have further shown that CD8+ T cell responses are normal, but classical NK cell effector functions 
are not detectable, implicating a severe and selective NK cell deficiency (113). E4bp4 is 
expressed in NKPs, is upregulated in iNKs and maintained in mNK cells. As described above, 
trans-presentation of IL-15 by membrane bound IL-15 receptor α chain represents the essential 
fuel that drives the differentiation from NKPs to iNK cells. The E4bp4 expression pattern 
coincides with the IL-15 dependency of the different NK cell developmental stages. This suggests 
that E4BP4 is the critical transcription factor mediating the biological effects of IL-15. 
Interestingly, Gascoyne et al have shown that the expression of ID2 is much lower in E4BP4 
deficient hematopoietic precursors and that E4BP4 induces the expression of ID2 as well as 
ectopic expression of ID2 partially restores NK cell development in vivo. Taken together, these 
data suggests ID2 as target of E4BP4 in early lymphoid precursors, which can then promote NK 
cell fate (124). 
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2 
AIM OF THE THESIS 
The importance of NK cells in tumor surveillance has been shown previously in vitro as well as in 
vivo. Besides tumor cells, NK cells recognize and lyse cells infected by viruses or parasites. 
Moreover, NK cells secrete cytokines such as IL-13, IFNγ and TNF that stimulate the adaptive and 
the innate immune system. Thereby, NK cells accomplish an important role in orchestrating the 
interplay of the innate and adaptive immunity. A great deal of progress has been made in 
delineating NK cell effector functions, however, the molecular basis of NK cell development and 
its transcriptional machinery behind is not well understood and has been proposed as one of the 
most important problems to be addressed in NK cell biology. A better understanding of how NK 
cells develop into potent effector cells is a prerequisite for understanding their contribution to 
disease processes as well as for investigating their therapeutic potential. Deletion of key 
regulatory genes often results in severe phenotypes that interfere with the analysis of a 
particular cell type. Furthermore, due to redundancies within gene families, other members 
might compensate for the loss of target genes. Therefore, global deletion of a certain gene often 
limits the interpretation of an achieved phenotype. To overcome these problems, conditional 
gene inactivation with the loxP-Cre system has been widely used. However, until now, no NK cell 
specific Cre line has been reported. 
To study NK cell specific functions of the transcription factor STAT5, we generated a mouse line 
that expresses the Cre recombinase specifically in NK cells. Therefore, we used a BAC transgenic 
approach where we expressed the Cre recombinase under the control of the Ncr1 (p46) 
promoter. We verified the functionality and lineage specificity by crossing Ncr1iCre mice with the 
EGFPLSL reporter mouse line. To exclude any possible toxic effects of the Cre expression per se, 
we performed a comprehensive analysis of NK cell development and effector function in vitro 
and in vivo in Ncr1iCre mice. Finally, we bred the Ncr1iCre mice with Stat5f/f mice to specifically 
delete Stat5 in NK cells and to elucidate the possible roles of STAT5 for NK cell development and 
function. 
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3 
RESULTS 
This section consists of 5 manuscripts. The results from the main project of my doctoral thesis 
are described in 3.1. Additionally, I contributed to several other studies during my PhD and the 
results from these projects are described in section 3.2, 3.3, 3.4 and 3.5. 
 
3.1 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK cell survival and 
development. 
Eva Eckelhart1, Wolfgang Warsch1, Eva-Maria Zebedin1, Olivia Simma1 a, Dagmar 
Stoiber2, Thomas Kolbe3, Thomas Rülicke3, Mathias Mueller3, Emilio Casanova2 * and 
Veronika Sexl1 *. Manuscript in revision (Blood) 
3.2 Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in 
the treatment of ovarian cancer. 
Ahmed El-Gazzar1, Paul Perco5, Eva Eckelhart2, Mariam Anees1, Veronika Sexl2, Bernd 
Mayer5, Yanxin Liu6, Wolfgang Mikulits3, Reinhard Horvat4, Thomas Pangerl1, Dexian 
Zheng6 and Michael Krainer1. Manuscript published in Mol Cancer Ther 2010 
Apr;9(4):1007-18 
3.3 STAT5 is an important mediator of imatinib resistance in Abelson-induced leukemia. 
Wolfgang Warsch*, Karoline Kollmann*, Eva Eckelhart*, Sabine Fajmann*, Sabine 
Cerny-Reiterer+, Andrea Hölbl*, Karoline V. Gleixner+, Michael Dworzak§, Christian 
Sillaber+, Gerda Egger$, Peter Valent+,#,Richard Moriggl& and Veronika Sexl*. Manuscript 
in revision (Blood) 
3.4 C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 
5’ region of Cdk6. 
Karoline Kollmann1, Gerwin Heller2, Rene Georg Ott1, Ruth Scheicher1, Eva Zebedin-
Brandl1, Olivia Simma1, Wolfgang Warsch1, Eva Eckelhart1, Christine Schneckenleithner1, 
Andrea Hoelbl1, Sabine Zöchbauer-Müller2, Marcos Malumbres and Veronika Sexl1. 
 Manuscript under review (Blood) 
3.5 Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor 
surveillance. 
Results | 30 
 
Eva Zebedin1, Olivia Simma1, Christian Schuster1, Eva Maria Putz1, Sabine Fajmann1, 
Wolfgang Warsch1, Eva Eckelhart1, Dagmar Stoiber2, Eva Weisz2, Johannes A. Schmid2, 
Winfried F. Pickl3, Christian Baumgartner4, Peter Valent4, Roland P. Piekorz5, Michael 
Freissmuth1, and Veronika Sexl1. Manuscript published in Blood. 2008 Dec 
1;112(12):4655-64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results | 31 
 
3.1 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for  
NK cell survival and development. 
 
Manuscript in revision (Blood). 
 
Eva Eckelhart1, Wolfgang Warsch1, Eva-Maria Zebedin1, Olivia Simma1 a, Dagmar Stoiber2, 
Thomas Kolbe3, Thomas Rülicke3, Mathias Mueller3, Emilio Casanova2 * and Veronika Sexl1 *. 
 
1Institute of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical 
University of Vienna, Austria; 2Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 
Austria; 3Biomodels Austria, Institute of Laboratory Animal Science, Institute of Animal Breeding 
and Genetics, University of Veterinary Medicine Vienna, Austria. 
 
  
Results | 32 
 
ABSTRACT 
We have generated a transgenic mouse line that expresses the Cre recombinase under the 
control of the NcrI (p46) promoter. Cre mediated recombination was tightly restricted to natural 
killer (NK) cells as revealed by crossing NcrIiCre mice to the EGFPLSL reporter strain. NcrIiCre mice 
were further used to study NK cell specific functions of Stat5 by generating Stat5f/f NcrIiCre 
animals. Stat5f/f NcrIiCre mice were largely devoid of NK cells in peripheral lymphoid organs. In the 
bone marrow, NK cell maturation was abrogated at the NK cell precursor (NKP) stage. Moreover, 
we found that in vitro deletion of Stat5 in IL-2 expanded NK cells was incompatible with NK cell 
viability. In vivo assays confirmed the complete abrogation of NK cell mediated tumor control 
against B16F10 melanoma cells. In contrast, T cell mediated tumor surveillance against MC38 
adenocarcinoma cells was undisturbed. In summary, our study shows a cell intrinsic role for 
STAT5 for NK cell development and reveals that NcrIiCre mice are a powerful novel tool to study 
NK cell development, biology and function. 
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INTRODUCTION 
NK cells are members of the innate immune system and represent a third lineage of lymphoid 
cells distinct from T and B lymphocytes. NK cells were initially discovered through their ability to 
spontaneously lyse tumor cells.1 The importance of NK cells in tumor surveillance has been 
shown in vitro as well as in vivo in different mouse models.2,3 Besides tumor cells, NK cells 
recognize and eliminate cells infected by certain viruses or parasites.4-6 In addition, NK cells 
produce and secrete cytokines such as interferon (IFN)-γ and tumor necrosis factor (TNF) that 
stimulate the adaptive and the innate immune response.7,8 Thereby, NK cells exert an important 
function in orchestrating the interplay of innate and adaptive immunity. 
In adult mice, NK cell differentiation takes place mainly in the bone marrow.9 The earliest NKPs 
are characterized by the expression of the IL-2 and IL-15 receptor common ß subunit, also 
known as CD122, and the absence of NK lineage markers such as NK1.1, DX5 and Ly49 
receptors.10 This cell type gives rise to immature NK (iNK) cells, which are positive for NK1.1, 
negative for DX5 and display reduced expression of certain Ly49 receptors. Further 
differentiation comprises mature NK (mNK) cells expressing NK1.1, DX5 and Ly49 receptors. 
Mature NK cells may leave the bone marrow and migrate to secondary lymphoid organs, lung, 
liver and gut. Recently, IL-22 producing lymphoid cells in the intestinal lamina propria have been 
characterized which are positive for NCRI, NKG2D and NK1.1, and express the orphan 
transcription factor RORyt.11. However, NKPs and iNKs are not uniquely restricted to the bone 
marrow since they have been found at other sites such as the spleen12 and the lymph nodes.13 It 
has therefore been suggested either that multiple sites may support NK cell differentiation or, 
alternatively, NKPs and iNKs from the bone marrow have access to the circulation. As NK cells 
maturate, they sequentially acquire their characteristic NK cell receptor repertoire.14,15 The 
natural cytotoxicity receptor I (NCRI), also known as NKp46, becomes expressed during the early 
iNK cell stage and remains constitutively expressed.16,17 The ligand(s) of this receptor are only 
partially characterized.18,19 NCRI is involved in the control of influenza infection by recognizing 
the viral hemagglutinin protein16 and has most recently been identified as factor modulating 
disease progression in type I diabetes.20 Developmental pathways generating the NK cell 
diversity including the transcriptional machinery behind is not well understood and remains 
elusive. 
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The differentiation and homeostasis of lymphocytes are regulated by cytokines such as the 
interleukins IL-2, IL-4, IL-7, IL-15 and IL-21. All these cytokines require the common γ chain (γc) 
and activate major signaling pathways such as that involving the Janus family of tyrosine kinases 
(JAKs) and signal transducers and activators of transcription (STATs) thereby contributing to the 
biological effects of lymphoid cells.21 The JAKs are stably associated with the cytokine receptor 
and induce the activation of STATs upon receptor stimulation with STAT5 being predominantly 
activated by IL-2, IL-7 and IL-15.22 STAT5 consists of two highly homologous isoforms, STAT5A 
and STAT5B, encoded by separate genes. In the lymphoid system, STAT5A/B fulfils largely 
redundant roles, although STAT5B has been implicated in NK cell development.23 In Stat5b-/- 
mice, NK cell numbers were found to be reduced to 50% and whole splenocyte cultures showed 
a reduced cytolytic capacity in response to IL-2 and IL-15 which was attributed to the NK cell 
compartment.24 
The generation of mice deficient for both, Stat5a and Stat5b (Stat5a/b), verified their important 
role for lymphoid development and homeostasis. The first Stat5a/b knock out mouse expressed 
N-terminally truncated proteins at various expression levels depending on the tissue type and 
led to a viable phenotype (now referred to as Stat5ΔN/ΔN mice). The residual STAT5ΔN proteins 
bind DNA and activate transcription of some, but not all target genes23. Furthermore, STAT5ΔN 
proteins are constitutively active even in the absence of cytokines. Therefore, the interpretation 
of phenotypes obtained with Stat5ΔN/ΔN mice is complex and requires revalidation in a model 
completely devoid of STAT5 proteins. This is most obviously seen in the fact that mice lacking 
complete Stat5a/b die perinatally whereas Stat5ΔN/ΔN animals are viable.25 Stat5a/bf/f mice 
(henceforth Stat5f/f mice) crossed to B and T cell specific Cre lines revealed multiple and complex 
functions of STAT5A/B (henceforth STAT5). In B cells, STAT5 mediates survival downstream of IL-
7 and is involved in immunoglobulin rearrangement and pre-B cell expansion.26,27 Within the T 
lymphoid lineage, STAT5 is mainly required for the expansion of CD8+ T cells and TCRγδ 
lymphocytes.28 The key role of STAT5 in lymphoid cells is also underlined by the fact that STAT5 
is constitutively active in many lymphoid malignancies which may even critically depend on its 
presence.29 
In this study we describe the successful generation of a mouse model that allows for the first 
time the conditional mutagenesis specifically in NK cells. Our work reveals a critical role for the 
transcription factor STAT5 for NK cell development and survival. In Stat5f/f NcrIiCre mice, NK cells 
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are nearly completely absent causing the virtual abrogation of NK cell mediated tumor 
surveillance without affecting T cell controlled immune surveillance. 
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RESULTS 
Generation and characterization of NcrIiCre mice 
In order to restrict Cre recombinase expression to NK cells, we generated transgenic mice 
expressing the Cre recombinase under the control of the NcrI promoter (schematically illustrated 
in Figure 1A). We used a BAC clone containing the entire NcrI gene along with abundant 
upstream and downstream flanking DNA. By homologous recombination in bacteria, the coding 
part of the first exon of NcrI was replaced by the iCre expression cassette. To test the 
functionality and lineage specificity, NcrIiCre transgenic mice were crossed to the EGFPLSL reporter 
mouse line that expresses enhanced green fluorescent protein (EGFP) upon Cre mediated 
excision of a loxP-flanked stop cassette.31 As depicted in Figure 1B, EGFP expression in CD3-DX5+ 
NK cells varied between 70% - 90% in individual NcrIiCre EGFPLSL double transgenic mice. In 
average, we observed 85.33% ± 3.79% of EGFP+ NK cells in the spleen, 72.93% ± 2.61% in the 
bone marrow, 74.53% ± 5.06% in lymph nodes, 80.57% ± 2.98% in the blood (summarized in 
Figure S1). No EGFP expression was detected in T lymphoid cells as analyzed by CD3, CD4 and 
CD8 staining (Figure 1C). Despite the general agreement that NCRI is constitutively and 
selectively expressed in NK cells34 it has been described to be expressed in peripheral NK-like 
TCRγδ cells.35 Hence, to unequivocally define EGFP expression in those cells, we stained 
splenocytes from NcrIiCre EGFP mice for NK1.1 and CD1d tetramer, and TCRαβ and TCRγδ. As 
depicted in Figure 1D and Figure 1E, we failed to observe any EGFP expression in NKT and TCRγδ 
cells. Similarly, we failed to detect EGFP+ B lymphoid cells (Figure 1F). In addition, we confirmed 
the exclusive NcrI dependent Cre recombination by staining of splenocytes with TCRβ, NK1.1 and 
NKp46. As expected, EGFP+ cells were constricted to the NK cell compartment (TCRβ-
NK1.1+NKp46+) (Figure 1G). We therefore concluded that Cre recombination in NcrIiCre mice is 
restricted to the NK cells. 
 
Cre expression does not alter NK cell development and function 
Although Cre recombinase has been intensively used to induce genomic recombination, Cre 
expression has been reported to be toxic for some eukaryotic cells.36,37 This was related to 
chromosomal rearrangements caused by recombination between cryptic “pseudo-loxP” sites 
naturally occurring within the genome. Alternatively, integration of the transgene might have 
disrupted genes important for organ and/or cell development. We therefore next studied the 
effects of Cre expression per se on NK cell development and function. NcrIiCre transgenic mice 
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were born at the expected Mendelian ratio without any visible alterations in organ morphology 
or overt pathology (data not shown). NK cells develop mainly in the bone marrow. Basically, 
three major developmental stages can be distinguished defined by their NK1.1 and DX5 
expression.9 NKPs at the first developmental stage are negative for NK1.1 and DX5, iNKs express 
NK1.1 but not DX5, and mNKs are positive for both, NK1.1 and DX5. At the iNK cell stage, NCRI is 
expressed and remains expressed throughout all stages17 (schematically illustrated in Figure 2A). 
No changes in NKPs (Lin-CD122+NK1.1-DX5-) in the bone marrow of NcrIiCre transgenic mice were 
detected compared to wild type littermate controls (Figure 2B). Also, peripheral mature NK cells 
were present at equal levels in spleen, lymph nodes and blood (Figure 2C). Mature NK cells in 
the spleen are further subdivided into functionally distinct subsets depending on CD27 and 
CD11b expression. A four-stage process from CD11blowCD27low to CD11blowCD27high to 
CD11bhighCD27high to CD11bhighCD27low is thought to reflect the developmental program 
associated with a progressive acquisition of NK cell effector functions.38 Again, analysis of the 
surface marker CD27 and CD11b revealed an unaltered NK cell maturation in NcrIiCre mice (Figure 
2D). Similarly, in vivo NK cell proliferation in the spleen using BrdU incorporation and in vitro 
proliferation of IL-2 cultured NK cells was unaffected (Figure 2E and 2F). Finally, given that lysis 
of target cells is a major NK cell function, we performed in vitro cytotoxicity assays using MACS 
purified IL-2-expanded splenic NK cells derived from NcrIiCre mice and their littermate controls. 
Figure 2G summarizes our efforts. YAC-1 cells that express low levels of MHC I were used as 
target cells as well as RMA-Rae1γ cells expressing the NKG2D ligand Rae-1.39 RMA cells served as 
a negative control since they are not efficiently lysed by syngeneic NK cells. In summary, all 
results were similar irrespective of the target cells used. No differences in the killing activity of 
NcrIiCre and their littermate controls were detectable. Overall, these experiments suggest that 
Cre expression in NK cells neither impairs NK cell development nor NK cell function. 
 
NK cells are severely reduced in Stat5f/f NcrIiCre mice 
The transcription factor STAT5 is an important regulator of B and T lymphoid cell development 
and function.27,28 To investigate the role of STAT5 in NK cells, we crossed Stat5f/f mice to NcrIiCre 
transgenic animals. Stat5f/f NcrIiCre mice were born at the expected Mendelian ratio (data not 
shown). Hematopoietic organs displayed no gross abnormalities; weight and cellularity of 
spleen, cellularity of the thymus and bone marrow were unaltered in Stat5f/f NcrIiCre mice 
compared to Stat5f/f littermate controls (data not shown and Figure S2). Analysis of CD3-DX5+ 
cells in spleen and lymph nodes revealed a severe reduction of NK cells in Stat5f/f NcrIiCre mice. 
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The NK cell population was almost entirely absent (82% ± 7.1% reduction in the spleen, 77.5% ± 
4.7% in the lymph nodes) (Figures 3A-B). Figure 3C shows the total NK cell number in the spleen. 
In contrast, no changes in the T cell compartment were observed. The numbers of CD4+ and 
CD8+ T lymphocytes and CD4/CD8 ratios were unaltered in thymus and secondary lymphoid 
organs (Figures 3D-E). 
The few remaining MACS purified NK cells from Stat5f/f NcrIiCre spleens showed a PCR band 
indicative for the deletion of Stat5 which was neither present in the Stat5f/f fraction nor in the 
NK cell depleted flow-through (Figure 4A). We noticed however that the Stat5 deletion was 
incomplete since Stat5a/b mRNA levels of sorted splenic NK cells were not affected in Stat5f/f 
NcrIiCre NK cells (Figure 4B). We reasoned that the absence of STAT5 is incompatible with NK cell 
viability. This was supported by the following observation: when we cultivated purified Stat5f/f 
derived NK cells in IL-2, the cells expanded as expected (data not shown). In contrast, the Stat5f/f 
NcrIiCre derived NK cells did not significantly expand (data not shown). After 6 days in culture, 
only few Stat5f/f NcrIiCre derived NK cells were present. Importantly, these few remaining NK cells 
were all escapers and expressed STAT5 indicated by the lack of a Stat5 deletion band, as 
analyzed by PCR (Figure 4C, left panel). The NK cell nature of these remaining cells was 
confirmed by their CD3-DX5+ surface expression, depicted in Figure 4C, right panel. To 
substantiate these finding, we purified and cultivated NK cells derived from Stat5f/f animals. 
After 3 days of expansion in IL-2, the cells were infected with an adenovirus expressing Cre 
recombinase (Ad/Cre-GFP) or mock infected (Ad/GFP). Figure 4D summarizes our efforts: 
Whereas the NK cells tolerated the expression of Ad/GFP, NK cells that had received Ad/Cre-GFP 
had a disadvantage and declined (Figure 4D, left panel). The deletion of Stat5 was confirmed by 
PCR analysis (Figure 4D, right panel). 
 
STAT5 is required for NK cell development from the NKP to the iNK cell stage 
Our data so far indicated, that the lack of STAT5 does not allow the survival of splenic NK cells 
and that STAT5 is indispensable for the viability of NK cells. We next investigated, whether the 
lack of STAT5 would affect NK cell differentiation in the bone marrow. As depicted in Figure 5A-
B, flow cytometric analysis of Stat5f/f and Stat5f/f NcrIiCre bone marrow cells confirmed a 
significant decrease of mNK cells. In contrast, the NcrIiCre dependent deletion of Stat5 was 
accompanied by an increase in NKP numbers. This increase of NKPs points at a developmental 
block occurring at the very first stage of NK cell development. Moreover, flow cytometric 
analysis of several NK cell markers unveiled lower levels of the activatory receptor Ly49D 
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whereas the levels of the inhibitory receptors Ly49C+I was higher. In contrast, the levels of CD94 
and NKG2D were comparable between the two genotypes. This finding reflects the immature 
nature of Stat5f/f NcrIiCre derived NK cells in the bone marrow (Figure 5C). 
 
Severe impairment of NK cell dependent, but not T cell dependent tumor surveillance in 
Stat5f/f NcrIiCre mice 
NK cells are well known for their tumor suppressive role.40,41 To investigate whether the NcrIiCre 
dependent deletion of Stat5 is of functional consequence and affects NK cell mediated 
antitumor activity, we made use of B16F10 melanoma cells. B16F10 cells display low MHC class I 
levels indicating a role for NK cells in tumor clearance (Figure S3). To verify that these cells are 
indeed exclusively under the tumor surveillance of NK cells, we injected the tumor cell line i.v. 
into wild type mice (WT). These mice were subsequently either depleted for NK cells or cytotoxic 
T cells by using antibodies directed against NK1.1 and CD8. 21 days thereafter, the experiment 
was terminated and lung metastases were counted. As depicted in Figure 6A-B, depletion of 
NK1.1+ cells significantly enhanced the formation of tumor nodules in the lung. In contrast, no 
differences were observed when CD8+ T cells were depleted compared to the WT. Hence, we 
next challenged Stat5f/f NcrIiCre mice and control animals with B16F10 cells. After 12 days the 
experiment was terminated. Stat5f/f NcrIiCre mice showed a profound cell infiltration in the lungs. 
In contrast, only few infiltrating tumor cells were found in the control Stat5f/f animals (Figure 6C-
D). These data revealed the strongly impaired NK cell dependent tumor surveillance in Stat5f/f 
NcrIiCre mice. We wondered, whether this severe defect in NK cell development and function 
would affect T cell mediated tumor surveillance. To test this, we used MC38 adenocarcinoma 
cells. MC38 tumor cells display high MHC class I levels pointing to a CTL mediated target cell 
recognition (Figure S3). Indeed, these cells are recognized and lysed by CD8+ cytotoxic T cells as 
verified by antibody dependent depletion of either NK cells or CD8+ T cells (Figure 6E). In this 
case, only the depletion of CD8+ cells significantly enhanced tumor formation, whereas the 
repeated application of anti-NK1.1 antibody had no effect compared to the WT. When MC38 
cells were s.c. injected into Stat5f/f NcrIiCre mice and Stat5f/f littermate controls, we failed to 
detect any changes in tumor formation between the two genotypes (Figure 6F). Similarly, upon T 
cell activation in vitro, we did not detect alterations in the expression of activation markers such 
as CD44 and CD25 on CD3+CD8+ T cells purified from Stat5f/f NcrIiCre versus Stat5f/f mice (Figure 
6G). 
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MATERIALS AND METHODS 
Generation of NcrIiCre transgenic mice 
The iCre recombinase was inserted into a Bacterial Artificial Chromosome (BAC, RP23-267N11, 
purchased from the Children’s Hospital Oakland Institute) harboring the NcrI gene via 
homologous recombination in E. coli as previously described.30 Briefly, a cassette containing iCre 
recombinase, an artificial intron, a bovine growth hormone polyadenylation signal and an 
ampicillin resistance gene flanked by FRT sites was recombined into the first exon of the NcrI 
gene. Correctly recombined BACs were transiently electroporated with a plasmid expressing the 
Flp recombinase to delete the ampicillin gene. Correctly recombined BACs were verified by 
southern blot and sequencing. BAC DNA was digested with NotI, purified using a sepharose CL4b 
column, injected into the pronuclei of C57BL/6 oocytes. Three out of four NcrIiCre founders 
expressed the transgene, one was selected for detailed analysis. Genotyping of NcrIiCre mice was 
performed using the following primers: 5’GACCATGATGCTGGGTTTGGCCCAGATG and 
5’ATGCGGTGGGCTCTATGGCTTCTG yielding a 500-bp polymerase chain reaction (PCR) product.  
 
Mice 
All animals used were 4 to 12 weeks and maintained at the Biomedical Research Institute, 
Medical University of Vienna and at the University of Veterinary Medicine, Vienna. Stat5f/f and 
EGFPLSL mice were described previously. 25,31 All animal experiments were approved by the 
Federal Ministry for Science and Research. 
 
Antibodies and flow cytometric analysis 
The following antibodies were purchased from BD Bioscience: PE-Cy7-anti-NK-1.1 (PK136), APC-
anti-CD49b (HMα2), PerCP- and PE-anti-CD3e (145-2C11), FITC-anti-CD3 (17A2), FITC-anti-CD4 
(RM4-5), APC-anti-CD8a (53-6.7), PerCP-Cy5.5-anti-CD45R/B220, APC-Cy7-anti-CD19, PE-anti-γδ 
T-Cell Receptor (GL3), APC-anti-TCRβ (H57-597), PE or FITC-anti-CD122 (TM-Beta 1), biotin-anti-
Ly6G/Ly6C (RB6-8CM), biotin-anti-CD3e (145-2C11), biotin-anti-TER119, biotin-anti-
CD45R/B220/RA3-6B2), PE-anti-CD27 (LG3A10), PerCP-Cy5.5-anti-CD11b (M1/70), PE-anti-CD44 
(IM7) and APC-anti-CD25 (Pc61). PE-anti-NKp46 (29A1.4) was obtained from eBioscience. PBS57-
loaded and unloaded CD1d tetramers were generously donated by Wilfried Ellmeier (Medical 
University, Vienna). For flow cytometry, single-cell suspensions were prepared from various 
tissues; splenocytes were depleted of red blood cells. Purified rat-anti-mouse CD16/CD32 
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(2.4G2) (BD Pharmingen) was added to avoid nonspecific binding of monoclonal antibodies to 
FcγR. For intracellular staining, cells were fixed and permeabilized with paraformaldehyd. Briefly, 
cells were fixed with 2% paraformaldehyde at room temperature (RT) for 10 minutes and 
incubated with ice-cold methanol for 20 minutes at -20°C. Fc-receptors were blocked, cells were 
incubated with STAT5 (C17; Santa Cruz) at 4°C over night under agitation and counterstained 
with PE-conjugated goat-anti-rabbit IgG (Santa Cruz). For in vivo BrdU incorporation assays, mice 
were intraperitoneally (i.p.) injected with 1 mg BrdU (in 100 µl). After 12 hours, splenocytes 
were isolated, stained, fixed, permeabilized, and treated with DNase. Analysis of BrdU 
incorporation was performed using the BrdU Flow Kit (BD Pharmingen). Stained samples were 
analyzed using BD Bioscience FACSCantoII and FACSDiva software. 
 
NK cell purification, expansion and function 
NK cells were purified and expanded as previously described.32 Briefly, single-cell suspensions 
were prepared from at least 4 spleens per genotype. For NK cell purification, cell suspensions 
were incubated with anti-DX5-coated MACS beads (Miltenyi Biotec) and purified by LS columns 
on a MACS separator (Miltenyi Biotec). NK cells were expanded for 6-10 days in media (RPMI 
1640 containing 10% FCS, ß-2ME, L-glutamine, penicillin/streptomycin) supplemented with rhIL-
2 (henceforth IL-2) (5000 U/ml). The purity of NK cells was assessed by flow cytometry and was 
routinely >90% - 95%. For cell sorting, splenocytes were depleted of red blood cells, incubated 
with anti-CD3 and anti-DX5 and sorted into a CD3-DX5+ population. For in vitro proliferation 
assays, purified NK cells at day 6 were seeded in flat bottom 96-well plates (1 x 105 cells/well) 
under IL-2 (5000 U/ml). Proliferation was measured by 3[H]-thymidine incorporation. NK cell 
cytotoxicity was analyzed by flow cytometry, as described previously.33 Briefly, 1 x 104 target 
cells/well were incubated with 5 µM CFSE (Invitrogen) for 6 minutes at 4°C in dark. Expanded NK 
cells at day 10 were co-incubated with CFSE labeled YAC-1, RMA and RMA-Rae1γ targets at 
indicated E:T ratios for 4 hours at 37°C and placed on ice. Propidium iodide (Sigma) was added to 
each well immediately before flow cytometry. Percent specific lysis was determined as 
described.33 To check the effects of Stat5 deletion in primary NK cells, Stat5f/f NK cells were 
purified, expanded for 3 days under IL-2 and infected with adenovirus either expressing GFP 
(Ad/GFP) or Cre-GFP (Ad/Cre-GFP) (both were kindly provided by Wolfgang Mikulits, Medical 
University of Vienna) and 7 µg/ml polybrene. GFP expression of CD3-DX5+ cells was tracked via 
flow cytometry. The day of the highest GFP expression was defined as day0. 
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T cell stimulation 
MACS sorted (Miltenyi Biotec) T cells (5 x 105 cells/well) were stimulated with plate-bound anti-
CD3ε (1 µg/ml) (145-2C11; BD Biosciences) and anti-CD28 (2 µg/ml) (37.51; BD Biosciences) on 
48-well plates in the presence of IL-2 (100 U/ml) for 48 hours. T cells were harvested after 5 days 
and analyzed by flow cytometry. 
 
Cell lines and tumor models 
B16F10 and MC38 cell lines were maintained in DMEM supplemented with 10% heat-inactivated 
FCS, 100 U/ml penicillin-streptomycin, 2 mmol/l L-glutamine and 5 µmol/l ß-mercaptoethanol. 
YAC-1, RMA and RMA-Rae1γ cells were maintained in RPMI-1640 supplemented with 10% heat-
inactivated FCS, 100 U/ml penicillin-streptomycin, 2 mmol/l L-glutamine and 5 µmol/l ß-
mercaptoethanol. Mice were injected intravenously (i.v.) with 1 x 106 B16F10 and 
subcutaneously (s.c.) with MC38 and monitored daily for disease onset. Tissues were isolated, 
weighed, fixed in 3.7% formaldehyde and analyzed. For NK1.1+ and CD8+ T cell depletion, 100 µg 
anti-NK1.1 antibody and anti-CD8 antibody was injected twice a week, starting 2 days before 
beginning the experiment. Anti-NK1.1 antibody and anti-CD8 antibody was purified from PK136-
cell supernatant and 53-6.72-cell supernatant, respectively. The effective deletion of the 
respective cell population was confirmed by flow cytometry of splenocytes. 
 
Real time PCR 
Total RNA was isolated using Tri Reagent (Sigma) according to the manufacturer’s instructions. 1 
µg of total RNA was used for cDNA synthesis using the GeneAmp RNA PCR Kit (Roche) and used 
for the RT-PCR reaction performed on an Eppendorf RealPlex cycler using Taq DNA Polymerase 
(5Prime) and SYBR Green. All experiments were performed in triplicates. The following primers 
were used: Stat5a Forward: CAGATCAAGCAAGTGGTCCC3’, Stat5a Reverse: 
TCGAGACTGTCCATGGGCC, Stat5b Forward: GGCAGGGTCAGTAACGGAAG, Stat5b Reverse: 
GGCTCTGCAAAGGCGTTGTC. Samples were normalized to GAPDH expression; Gapdh Forward: 
TCTCCTCTGACTTCAACAGCG, Gapdh Reverse: ACCACCCTGTTGCTGTAGCC 
 
Statistics 
Statistical analysis was performed by using Student´s t test. The P-values were defined as 
following: *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant. Data are expressed as 
mean ± SEM and analyzed by Graph Pad® software (San Diego, CA).   
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Figure 1 
 
Figure 2. Generation and characterization of NcrI
iCre
 mice. 
(A) Schematic illustration of the modified NcrI bacterial artificial chromosome (BAC). A codon improved 
Cre recombinase (iCre) cDNA was inserted by homologous recombination into the exon containing the 
translation initiation codon of a BAC harboring the mouse NcrI gene. (B) Efficiency of Cre mediated EGFP 
expression verified via flow cytometry of NcrI
iCre
 EGFP
LSL
 double transgenic mice and littermate controls. 
Excision of a stop cassette flanked by loxP sites leads to EGFP expression that can be analyzed by flow 
cytometry. Numbers adjacent to outlined areas indicate percentage of NK cells (CD3
-
DX5
+
) of various 
lymphoid organs. Histograms show the percentage of EGFP expression of gated NK cells. (C-F) Flow 
cytometry of NcrI
iCre
 EGFP
LSL
 double transgenic mice and their littermate controls showing the absence of 
EGFP expression in hematopoietic cell lineages other than NK cells. Dot plots indicate percentages of (C) 
gated CD3
+
 CD4
+
CD8
+
 cells (D) gated CD3
-
 NK1.1
+
CD1dtetra
+
 cells (E) gated CD3
+
 TCRγδ
+
 TCRβ
+
 cells (F) and 
B220
+
CD19
+
 cells. Histograms show the percentage of EGFP expression. (G) Almost all NK cells express 
EGFP. ~ 99% of gated TCRß
-
EGFP
+
 cells are NK cells (NK1.1
+
NKp46
+
). (n≥4 per genotype ). Data are 
representative of at least three independent experiments. BM: bone marrow, LN: lymph nodes 
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Figure 2 
 
Figure 2. Development and function is not altered in Cre expressing NK cells. 
Neither NK cell development nor their proliferation or cytotoxicity was influenced by Cre recombinase. (A) 
Simplified scheme of NCRI expression in NK cell development. (B-E) Flow cytometry of NcrI
iCre
 mice and 
littermate controls. Dot plots indicate percentage of (B) gated Lin
-
CD122
+ 
DX5
-
NK1.1
-
 NKPs in the BM (C) 
gated CD3
-
 NK cells (NK1.1
+
DX5
+
) in the periphery (D) and expression of maturation markers of splenic NK 
cells gated as TCRß
-
NK1.1
+ 
stained with CD27 and CD11b antibodies. (n≥4 per genotype). Data are 
representative of at least three independent experiments. (E) In vivo proliferation of splenic NK cells. Mice 
were injected i.p. with BrdU. After 12 hours, the incorporation of BrdU in splenic NK cells was analyzed. 
Numbers adjacent to outlined areas in the dot plot indicate percent CD3
-
NK1.1
+ 
cells. Histograms show the 
percentage of BrdU positive cells (n≥5 per genotype). Data are representative of two independent 
experiments. (F) In vitro proliferation of IL-2 expanded NK cells purified from the spleen of indicated 
genotypes. At day 6, NK cells were seeded in triplicates in 96-well plates. After 12 hours, proliferation was 
measured by standard 
3
[H]-thymidine incorporation. Four mice per genotype were pooled. Data are 
representative of two independent experiments. (G) Cytotoxicity of IL-2 expanded splenic NK cells purified 
from indicated genotypes. At day 10, NK cells were co-incubated in triplicates with CFSE labeled YAC-1, 
RMA-Rae1γ and RMA targets at indicated E:T ratios. Five mice per genotype were pooled. Data are 
representative of two independent experiments. 
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Figure 3 
 
 
 
Figure 3. NK cells are severely reduced in Stat5
f/f
 NcrI
iCre
 mice. 
Deletion of Stat5 results in severely diminished NK cell numbers. (A, D) Flow cytometry of Stat5
f/f
 NcrI
iCre
 
mice and littermate controls. Dot plots show percentage of (A) peripheral NK cells (D) and CD4 and CD8 
expression on cells from various lymphoid organs. Cells were gated on total thymocytes (upper panel), 
CD3
+
 lymph node cells (middle panel) and CD3
+ 
splenocytes (lower panel). (B) Bar graphs show percentage 
of peripheral NK cells (CD3
-
DX5
+
). (C) Bar graph indicates total splenic NK cell numbers. (E) Bar graphs 
show CD4 to CD8 ratio of total thymocytes (left panel), CD3
+
 lymph node cells (middle panel) and CD3
+
 
splenocytes (right panel). (A, D) Data are representative of three independent experiments. (n≥4 per 
genotype). (B, C, E) (n≥5 per genotype). 
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Figure 4 
 
 
 
Figure 4. Loss of STAT5 is incompatible with NK cell viability. 
(A) PCR genotyping of deleted Stat5 alleles in MACS purified splenic NK cells of Stat5
f/f
 and Stat5
f/f
 NcrI
iCre
 
mice. (Four mice per genotype were pooled). (B) Real time PCR analysis of Stat5a and Stat5b mRNA levels 
of sorted splenic CD3
-
DX5
+
 NK cells. (Ten mice per genotype were pooled). (C) MACS purified splenic NK 
cells were cultured under IL-2. After 6 days of culture only those cells which express Stat5 expanded as 
indicated by the lack of a Stat5 deletion band via PCR analysis (left panel). Flow cytometry confirmed the 
NK cell nature of those cells (right panel). Dot plot indicates CD3
-
DX5
+
 cells. (Four mice per genotype were 
pooled). (D) MACS purified splenic NK cells from Stat5
f/f
 mice were cultured under IL-2 (four mice per 
genotype were pooled) and infected with Ad/Cre-GFP and mock infected. Those cells that received the 
empty vector tolerated the expression of Ad/GFP, whereas those that had received Ad/Cre-GFP expressed 
the Cre recombinase and declined (left panel). PCR genotyping of the cells confirmed the deletion of Stat5 
in Ad/Cre-GFP infected NK cells (right panel). Data are representative of at least two independent 
experiments. FT: flow-through; Co: Control. 
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Figure 5 
 
 
 
Figure 5. STAT5 is required for early NK cell development in the bone marrow. 
(A) Flow cytometry of Stat5
f/f
 NcrI
iCre
 mice and littermate controls. Dot plots show percentage of gated Lin
-
CD122
+ 
NKPs
 
(DX5
-
NK1.1
-
) and gated Lin
-
CD122
+ 
mNKs (DX5
+
NK1.1
+
). (B) Bar graphs show percentage of 
NKPs and mNKs in the bone marrow (C) Histograms showing the expression of indicated differentiation 
markers in percent. (n≥4 per genotype). Data are representative of (A) four (C) and three independent 
experiments. 
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Figure 6 
 
 
 
Figure 6. Tumor surveillance of NK cell controlled tumors is missing in Stat5
f/f
 NcrI
iCre
 mice. 
(A-D) B16F10 cells were injected i.v. into (A) WT, WT depleted of CD8
+ 
cells, and WT depleted of NK1.1
+
 
cells (C) and Stat5
f/f
 and Stat5
f/f
 NcrI
iCre
 mice. Numbers of metastatic infiltrates per lung were counted 
under the binocular microscope after (A) 21 days (C) and 12 days. (B, D) One representative example of an 
infiltrated lung of the indicated genotype is shown. Upper panel: photographs, digital camera, Canon EOS 
300D. Lower panel: H&E stained histological lung sections; magnification, x100 Zeiss Axiolmager 21 (Jena, 
Germany) 10x objective, NA 0.25, air; camera: Pixelink Color, 1600 x 1200; Software: PixelNK Capture 3.0. 
(E-F) MC38 cells were injected s.c. into (E) WT, WT depleted of CD8
+
cells, and WT depleted of NK1.1
+
 cells 
(F) and Stat5
f/f 
and NcrI
iCre
 Stat5
f/f
. After 17 days of injection, tumor weights were analyzed. (G) Histograms 
showing CD44 (upper panel) and CD25 (lower panel) expression on in vitro activated T cells from indicated 
genotypes. CD8
+
 T cells were cultured under IL-2 and stimulated with plate-bound anti-CD3 plus anti-CD28 
antibodies. Cells were gated on CD3
+
CD8
+
 populations. Open histograms indicate percentage of CD44
+
 or 
CD25
+
 T cells. Gray histograms indicate unstimulated T cells. (A, C, E, F) (n≥5 per genotype). (G) (Five mice 
per genotype were pooled). Data are representative of three independent experiments.  
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Supplementary Figure 1 
 
 
 
Figure S1. Percentage of GFP
+
 NK cells in various tissues of NcrI
iCre/+ 
EGFP
+/- 
mice.  
Bar graphs showing the percentage of NK cells of various lymphoid tissues from NcrI
iCre
 EGFP
LSL
 double 
transgenic mice. (n≥4 per genotype). 
 
 
 
Supplementary Figure 2 
 
 
 
Figure S2. No differences in spleen weight or numbers of total splenocytes in Stat5
f/f
 NcrI
iCre
 mice 
compared to Stat5
f/f
 mice. 
Bar graphs show spleen weight (left panel) and total splenocytes (right panel) of indicated genotypes. (n≥6 
per genotype) 
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Supplementary Figure 3 
 
 
 
Figure S3. MHC class I levels of indicated tumor cell lines. 
Bar graphs show mean fluorescence intensitiy (MFI) of class I MHC on B16F10 and MC38 cell clones 
determined by flow cytometry. White bar graphs indicate negative control; black bar graphs display the 
indicated cell clone. 
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3.2 Natural immunity enhances the activity of a DR5 agonistic antibody 
and carboplatin in the treatment of ovarian cancer. 
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3.3 STAT5 is an important mediator of imatinib resistance in Abelson-
induced leukemia 
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ABSTRACT 
In BCR-ABL1+ leukemia, drug resistance is often associated with upregulation of BCR-ABL1 or 
multidrug transporters as well as BCR-ABL1 mutations. Here we show that the expression level 
of the transcription factor STAT5 is another parameter that determines the sensitivity of BCR-
ABL1+ cells against BCR-ABL1 tyrosine kinase inhibitors (TKI) such as imatinib, nilotinib or 
dasatinib. Abelson-transformed cells expressing high levels of STAT5 were found to be 
significantly less sensitive to TKI-induced apoptosis in vitro and in vivo. This protection requires 
tyrosine-phosphorylation of STAT5 and transcriptional activity. In support of this concept, under 
imatinib treatment and with disease progression, STAT5 mRNA and protein levels increased in 
patients with Ph+ chronic myeloid leukemia. Based on our data, we propose a model in which 
disease progression in BCR-ABL1+ leukemia leads to an upregulated expression of STAT5, which 
subsequently confers protection against TKI-induced apoptosis. This process provokes the 
selection of cells with high STAT5-expression during treatment with TKIs and suggests that STAT5 
may serve as a novel, attractive target to overcome imatinib resistance in BCR-ABL1+ leukemia.  
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INTRODUCTION 
More than 99% of all patients with chronic myeloid leukemia (CML) and about 30% of acute 
lymphoid leukemia (ALL) are characterized by the t(9;22)(q34;q11) translocation and the so 
called Philadelphia chromosome. Two different chimeric oncogenic tyrosine kinase products, 
p185BCR-ABL1 or p210BCR-ABL1, may be generated.1,2 Whereas p210BCR-ABL1 is associated with CML, 
p185BCR-ABL1 is almost exclusively found in ALL.3 The BCR-ABL1 oncoprotein promotes leukemia 
development by activating multiple signal transduction pathways that regulate cell proliferation, 
transformation and survival of hematopoietic cells. BCR-ABL1-induced ALL is characterized by an 
excess of lymphoblasts and usually shows rapid disease progression, whereas BCR-ABL1+ CML is 
a stem cell-derived disease with three distinct phases: (i) a chronic phase (CP) that may last for 
several years, (ii) an accelerated phase (AP), and (iii) a blast crisis (BC).4 
Therapy of BCR-ABL1-induced diseases was significantly improved by the development and 
application of small molecular weight inhibitors blocking the activity of the ABL1 kinase. Imatinib 
was the first substance, which became available by 2001, and was soon followed by other 
tyrosine kinase inhibitors (TKIs) such as dasatinib and nilotinib.5-7 All these TKIs target the 
enzymatic activity of the ABL1 tyrosine kinases, including c-ABL, v-ABL, and BCR-ABL1.6,8,9 
Imatinib has now become the standard first line therapy for all patients with CML. However, not 
all patients with CML respond equally well to imatinib.10 Moreover, about 15-25% of the patients 
that initially responded well acquire resistance against imatinib during therapy. The percentage 
of non-responders is even higher in an advanced phase of CML.10-12 These patients are treated 
with an increased imatinib dosage (600-800 mg per day), second generation BCR-ABL1 inhibitors, 
or with stem cell transplantation.13-18 The most frequently reported causes for resistance to TKIs 
in CML are mutations in the kinase domain of BCR-ABL1 with a reported frequency of 40 to 
90%.13,15,16 Other mechanisms include the upregulation of BCR-ABL1 or increased expression of 
the drug transporter ABCB1.14,18 Apart from these mechanisms, deregulation in signaling 
cascades and activation of specific signaling molecules like LYN have also been discussed in 
contributing to drug resistance in CML.19,20 
Signaling pathways activated by BCR-ABL1 include the PI3K-mTOR pathway, RAS/RAF/MEK/ERK 
pathway, and the JAK-STAT pathway.21-24 We have recently shown that STAT5 is absolutely 
required for the transformation of hematopoietic cells by BCR-ABL1 oncogenes.22,25 In this study, 
we investigated the effect of STAT5 on imatinib response in BCR-ABL1+ cells. We show that 
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imatinib resistance increases upon elevated STAT5 protein expression. Interestingly, this 
correlates with an upregulation of STAT5 in imatinib-resistant patients and patients with 
advanced stages of disease. Thereby our study defines STAT5 as a clinically relevant modulator 
of imatinib responsiveness. This may have implications for the understanding of drug resistance 
development and the evolution of CML from CP to advanced phases, as well as in the design of 
new drugs and new treatment approaches.   
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RESULTS 
Increased imatinib resistance in Abelson transformed cells upon maintenance in tissue culture 
Transformation of hematopoietic cells with p185BCR-ABL1 and v-ABL results in the outgrowth of 
growth-factor independent CD19+CD43+B220+ cells. We noted that different v-ABL transformed 
lymphoid pro B-cell clones (v-Abl+ cells) varied significantly in their response to imatinib. We 
asked whether these differences might be related to the time the cells had been in culture. V-
Abl+ cells that had been propagated for less than three months after the initial transformation 
event were defined as short term cultures (STCs). They were opposed by long term cultures 
(LTCs) that had been cultured for more than eight months. First, we compared cell numbers of 
LTCs and STCs upon imatinib treatment. Since LTCs proliferated slightly faster than STCs (Figure 
S1A), we set the individual controls to 100% to allow their comparison. As depicted in Figure 1A, 
STCs reacted with a pronounced decrease in cell numbers to 100 nM imatinib, whereas LTCs 
were affected to a significantly minor degree. This difference in imatinib sensitivity also became 
obvious when the cells were plated in growth-factor free methylcellulose (Figure 1B, 
summarized in Figure S1B). Whereas the ability of LTCs to form colonies in the presence of 100 
nM or 200 nM imatinib remained largely unchanged, a significant decrease was observed for 
STCs. Dose response curves confirmed the decreased imatinib-sensitivity of LTCs (IC50 STC = 0.35 
µM, IC50 LTC = 5.05 µM; Figure 1C). Immunoblots revealed that several molecules were 
expressed at elevated levels in LTCs compared to STCs (Figure 1D). Among the factors that were 
up-regulated were the STAT transcription factors. Quantitative analysis by ImageJ revealed a 
highly significant up-regulation of STAT5A/B. STAT1, STAT3 and c-ABL showed a less consistent 
pattern (Figure 1D, quantitative analysis Figure S1C). We asked whether the elevated expression 
of STAT transcription factors contributes to the reduced imatinib sensitivity in LTCs. Several 
factors have been shown to confer TKI resistance, but nothing was known about STAT factors. To 
test whether the up-regulation of individual STAT proteins are on their own of functional 
relevance, Stat1-/- and Stat3∆/∆ leukemic cell lines were treated with increasing concentrations of 
imatinib for 24 hours. No differences on imatinib-sensitivity were detectable  (Figure S1D, S1E 
and S1F).   
Low STAT5 protein levels are related to increased imatinib sensitivity in p210BCR-ABL1 and v-ABL 
dependent cells 
Stat5null/null cells cannot be transformed by BCR-ABL1 and v-ABL.22 To evaluate the impact of 
STAT5 on imatinib sensitivity, we prepared single cell suspensions of bone marrow (BM) from 
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Stat5+/+ and Stat5null/+ mice. Differences in the STAT5 protein levels of the BMs were verified via 
immunoblot (Figure S2A). These cells were infected with pMSCV-p210BCR-ABL1-IRES-GFP in 
StemPro medium. The initial infection rate was comparable between Stat5+/+ and Stat5null/+ cells 
and varied between 10-20% in individual experiments. After three days the cells were kept 
under cytokine free conditions which increased the percentage of GFP+ cells to 30-50% after five 
days. The majority of the GFP+ and hence BCR-ABL1+ cells expressed the myeloid surface-marker 
MAC-1 (Figure S2B). The cells were then treated with increasing concentrations of imatinib for 
48 hours. Imatinib reduced the viability and cell numbers of the BCR-ABL1+/GFP+ cells without 
affecting the BCR-ABL1 negative population. As additional control naiive BM was treated with 
Imatinib, which did not exert any effect irrespective of the genotype. In contrast and as depicted 
in Figure 2A and 2B Stat5null/+ cells showed a significantly stronger reduction of viable BCR-
ABL1+/GFP+ cells when compared to BCR-ABL1+/GFP+ Stat5+/+ cells. Similar results were obtained 
with two individual p210BCR-ABL1 transformed Stat5fl/+ Rosa-Cre-ERT2 cell lines that express the 
progenitor markers c-KIT and SCA-1 (Figure S2C and S2D). Deletion of one Stat5a/b allele by 
Tamoxifen treatment enhanced cell death to imatinib exposure.    
Our observations were confirmed in v-ABL transformed lymphoid cells. Cell lines derived from 
Stat5null/+ fetal livers display a ~ 50% decreased STAT5 protein expression when quantified by 
ImageJ software when compared to v-Abl+ Stat5+/+ cells (Figure 2C). In contrast, no differences in 
v-ABL expression were detected. Determination of IC50 values upon imatinib treatment in the 
Stat5null/+ STC revealed a more than 10-fold difference (IC50 Stat5
null/+ = 31 nM, IC50 wild type = 353 
nM; Figure 2D). The increased imatinib sensitivity of Stat5null/+ cells was also prominent when 
cells were seeded in growth-factor free methylcellulose in the presence of 10 or 100 nM imatinib 
(Figure 2E). AnnexinV stainings suggest that the underlying mechanism relies on increased 
apoptosis in Stat5null/+ cells. Significantly more cells underwent apoptosis in Stat5null/+ STCs 
compared to wild type controls upon treatment with 100 nM imatinib for 24 hours (Figure 2F 
and 2G). These experiments implicate STAT5 as a regulator of imatinib responsiveness. 
 
Enhanced expression of STAT5A reduces TKI -induced cytotoxicity 
Stat5null/+ cells may harbor additional developmental alterations that account for the differences 
in imatinib sensitivity. To exclude this possibility, we undertook the following experiment: We 
infected p185BCR-ABL1+ or v-Abl+ STCs with a pMSCV-Stat5A-eGFP based retrovirus to generate 
transformed B-cells that differ from vector controls solely by an elevated STAT5A expression. 
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One representative experiment is depicted in Figure 3A. We obtained an infection rate of about 
20% irrespective whether we used the empty vector or the vector encoding STAT5A (resulting in 
“S5ahigh cells”). Subsequently, we challenged the resulting mixed cell population of non-
transduced and transduced cells to increasing concentrations of imatinib. Of the viable cells, the 
percentage of GFP+ cells was analyzed using FACS 24 hours thereafter. The treatment of cells 
with imatinib did not change the percentage of GFP+ cells infected with empty vector (Figure 3A, 
lower panel). In contrast, cells expressing elevated levels of STAT5A were selected in the 
presence of imatinib. This was indicated by the increase in percentage of GFP+ - S5ahigh cells 
(Figure 3A, upper panel). The effect was most evident at a concentration of 1000 nM imatinib, 
where the percentage of S5ahigh cells increased from 20% to 56% within 24 hours. The 
experiment was repeated with comparable results using individually derived v-Abl+ cell lines (n = 
10) or p185BCR-ABL1+ cell lines (n = 5) (summarized in Figure 3B and 3C). The effects were 
reinforced when imatinib incubation time of v-Abl+ cells, at a concentration of 100 nM, was 
extended to 48 and 72 hours (Figure S3A). Similarly, long term incubations using low 
concentrations of imatinib (10 nM) were capable to select for S5ahigh cells over a period of two 
weeks (Figure S3B).  
To exclude that interaction of S5ahigh cells with non-infected cells in the mixed populations 
interferes with the imatinib response, v-Abl+ cells were sorted for GFP-expressing (S5ahigh) and 
non-expressing (S5alow) cells. FACS analysis for intracellular STAT5A/B and immunoblots 
confirmed higher STAT5 protein level in S5ahigh cells compared to S5alow cells (Figure 3D, inserted 
histograms and Figure S3C). The differences in imatinib sensitivity were even more pronounced 
than in the mixed cell populations. Starting at concentrations of 300 nM imatinib, S5ahigh cell 
lines had a significantly higher viability. All S5alow cells underwent apoptosis when exposed to 
1000 nM imatinib, whereas still ~60% of the S5ahigh cells remained viable after 48 hours (Figure 
3D). Cytospins confirmed these results (Figure 3E). These experiments clearly link enforced 
STAT5A expression to decreased imatinib sensitivity.  
We next tested whether the protective effect of elevated STAT5A protein levels is specific for 
imatinib or extends to other BCR-ABL1 kinase inhibitors. As depicted in Figure 3F, the protective 
effect of STAT5A was also observed in experiments employing dasatinib and nilotinib. Most 
importantly, the protective effect neither restricted to one BCR-ABL1 kinase inhibitor nor to our 
cellular system. We took advantage of p210BCR-ABL1 transformed Ba/F3 cells that additionally 
express a doxycycline-inducible dominant negative variant of STAT5A (S5a∆749).27 The expression 
Results | 76 
 
of S5a∆749 was induced for 48 hours by doxycycline treatment. A dosage of doxycycline was 
defined in preliminary experiments that induced S5a749 expression but had only a minor impact 
on the viability of the cells (data not shown). To delineate the combined effects of BCR-ABL1 
kinase inhibition and STAT5 inhibition, concentrations of the TKIs only slightly affecting the cells 
were used. The inhibitors imatinib, nilotonib or dasatinib were added 24 hours after doxycycline. 
As depicted in Figure 3G, the combined inhibition of STAT5 and p210BCR-ABL1 resulted in a 
significantly decreased viability compared to the inhibition of p210BCR-ABL1 alone. These 
experiments suggested that transcriptionally competent STAT5 regulates the sensitivity of v-ABL 
and BCR-ABL1 transformed cells towards BCR-ABL1 kinase inhibition.  
 
Transcriptional activity of STAT5 is required to confer protection from imatinib-induced 
apoptosis 
For transcriptional regulation, STAT5 is tyrosine phosphorylated, dimerizes and translocates to 
the nucleus, where it binds to DNA. To investigate whether enforced expression of STAT5 in 
Abelson transformed cells is accompanied by increased tyrosine phosphorylation, DNA binding, 
and transcriptional activity of STAT5, we undertook the following experiments: First, we 
quantified tyrosine phosphorylated STAT5 using intracellular FACS. As depicted in Figure 4A (left 
panel), higher levels of phosphorylated STAT5 were present in sorted S5ahigh cells compared to 
S5alow cells. Accordingly, S5ahigh cells showed increased amounts of DNA-bound-STAT5 verified by 
EMSA (Figure 4A, right panel). We next tested mRNA expression levels of critical STAT5 target 
genes implicated in survival or proliferation promotion of hematopoietic cells. Real-time (RT)-
PCRs for the STAT5 target genes Osm, Pim-1, Cis, c-Myc, Cyclin D2, Bcl-2 and Socs2 were 
performed. The mRNA levels of S5alow cells served as baseline. A clear upregulation of all 
analyzed mRNAs was detected in S5ahigh cell lines (Figure 4B). A recent publication describes the 
downregulation of STAT5 target genes as one of the earliest events after dasatinib treatment.34 
In line with this report, treatment with high concentrations of dasatinib for 3 hours strongly 
reduced STAT5 target gene mRNA levels, irrespective of the STAT5A expression level (Figure 4B). 
To investigate whether the transcriptional function of STAT5A accounts for the STAT5A mediated 
resistance against imatinib, we took advantage of different STAT5A mutants (depicted in Figure 
4C). cS5F is a constitutively active STAT5A mutant due to a S711F point mutation. S5a∆N lacks the 
N-terminal domain required for oligomerization, but is still capable of functioning as a 
transcription factor for some STAT5 target genes.29,32 S5aY/F lacks the critical tyrosine 
phosphorylation (pY) site on position aa693 and does not efficiently translocate to the nucleus, 
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S5aEE/AA has DNA-binding domain mutations (EE437/438AA) blocking efficient DNA binding to 
STAT5 response elements.30 Retroviral infection was used to express these mutants in wild type 
STCs. Cells were treated for 24 hours with imatinib and viable cells were analyzed for GFP-
expression by FACS. Wild type STAT5A, cS5F and S5a∆N mediated growth advantage compared to 
untransfected cells. In contrast, infection with the empty vector or STAT5A mutants incapable of 
DNA binding had no effect (Figure 4D). This experiment provided evidence that tyrosine 
phosphorylation and DNA binding of STAT5 are prerequisites for the protective effect against 
imatinib. In line with this finding, sorted S5ahigh cells showed only an insignificant reduction of 
pSTAT5 levels when treated with imatinib up to concentrations of 300 nM for 24 hours (Figure 
4E, upper panel). The pSTAT5 levels in S5ahigh cells were reduced to the levels observed in S5alow 
cells, only when we used concentrations of imatinib as high as 1000 nM. This was accompanied 
by apoptosis after 72 hours of treatment, underscoring a close correlation of pSTAT5 level and 
imatinib sensitivity (Figure 4E, lower panel). In contrast, phosphorylation of STAT5 in S5alow cells 
was already blocked at an imatinib concentration of 300 nM, accompanied by apoptosis. We 
conclude that only tyrosine phosphorylated and transcriptional active STAT5 confers protection 
against imatinib and that a certain threshold of pSTAT5 is required to enable Abelson 
transformed cells to survive. 
 
STAT5 expression in leukemic cells of CML patients increases during disease progression 
We next analyzed STAT5 levels during disease progression in order to determine the significance 
of our data for patients suffering from CML. To address this, peripheral blood (PB) or BM derived 
leukemic cells of untreated patients at the time point of diagnosis were collected. Thirteen 
patients were in CP and seven in AP at the time point of collection. STAT5A mRNA levels were 
determined by RT-PCR and BM from three healthy patients served as control. A significant 
increase of STAT5A mRNA was found in samples obtained from patients in AP compared to CP 
(Figure 5A). These data correlate with the recommended dosage of imatinib for CP, which is 400-
600 mg/day and increases to 600-800 mg/day when the leukemia progresses to AP. In addition, 
we tested eight samples from imatinib treated patients, six in CP, one in AP and one in BC that 
had developed imatinib resistance and relapsed. 40% - 90% of cases of imatinib resistance are a 
result of mutations within the kinase domain of BCR-ABL1.35  Although all of our analyzed 
imatinib-resistante CML patients were tested positive for BCR-ABL1 mutations, a significant up-
regulation of STAT5A mRNA compared to patients with imatinib sensitive CP was registered. The 
international scale (IS) value for BCR-ABL1 mRNA level and detected BCR-ABL1 mutations are 
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depicted (analyzed BCR-ABL1 mutations listed in Figure S4A). Similar results were obtained for 
STAT5B mRNA when samples from three healthy and nineteen CML diseased patients (eight in 
CP, six in AP and five imatinib-resistant patients, three of them in CP, one in AP and one in BC) 
were analyzed (Figure S4B). The increase in STAT5 mRNA is reflected by changes in protein 
expression levels: patients suffering from CML in AP or imatinib-resistant CP display higher 
STAT5 protein levels (Figure 5B). In one sample (patient #32) we failed to detect STAT5 protein 
even after prolonged exposure for unknown reasons. To control for the quality of the patient 
samples additional to ß-Actin we analyzed the protein expression of CDK2, CDK4 and α-Tubulin 
which were comparable between the disease phases (Figure S4C). Expression of activated STAT5 
(pSTAT5) in primary CML cells was further confirmed by immunocytochemistry. In these 
experiments, the anti-pSTAT5 antibody AX1 was found to react with primary CML cells. The 
percentage of pSTAT5+ cells varied among patients. In most patients with CP, only a few cells 
stained positive for pSTAT5, whereas higher counts were recorded in AP and BC (Figure 5C and 
Table 1) consistent with our previous findings. Furthermore, the pSTAT5-intensity, which reflects 
the amount of STAT5 proteins in untreated cells, was elevated in AP and BC. Interestingly, even 
in BC, not all clonal cells (blasts) were found to react with the anti-pSTAT5 antibody.  
The upregulation of STAT5 was restricted to BCR-ABL1+ disease, since two samples of CML 
patients in BCR-ABL1-negative BC (48% and 50% PB blasts) and two patients with secondary AML 
(26% and 85% PB blasts) did not show significant changes in STAT5 mRNA levels (Figure 5D). The 
upregulation of STAT5 can therefore not be explained by a shift in cellular populations such as 
the presence of increased numbers of immature cells and blasts in the BCR-ABL1+ samples 
investigated. Since in these BCR-ABL1-negative cells the BCR-ABL1-driven constitutive activation 
of STAT5 is missing, we speculated that activated STAT5 promotes its own transcription, leading 
to its upregulation. First evidence supports this concept; the enforced expression of wild type 
STAT5A or constitutive active STAT5A (cS5aF) in v-ABL of p210BCR-ABL1 dependent cells induces 
STAT5B expression and vice versa (Figure S4D). It is attractive to speculate that this feed-forward 
loop, combined with an imatinib-induced selection pressure, accounts for the upregulation of 
STAT5 as observed in CML-patients. 
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Ectopic expression of STAT5A renders v-ABL transformed cells resistant to in vivo treatment 
with imatinib  
The data obtained so far encouraged us to challenge our concept in an in vivo experimental 
setting. To mimic the situation of leukemic patients undergoing imatinib treatment, we injected 
NOD/SCID mice with v-Abl+ cells. We prepared wild type STCs that contained 99% of uninfected 
cells (S5alow) enriched by 1% of cells infected with pMSCV-Stat5A-IRES-GFP (S5ahigh). Thus, S5ahigh 
cells are indicated by GFP expression (Figure 6A, upper middle panel). 2x106 cells/mouse were 
injected intravenously and the animals showed first signs of disease such as reduced mobility 
and scrubby fur 13 days thereafter. Blood samples were taken, which revealed the presence of 
significant amounts of leukemic cells. About 80% of the cells in the PB expressed CD19 and were 
therefore classified as leukemic cells. No change in the composition of S5ahigh versus S5alow cells 
was detectable. Still, 1% of the leukemic cells were GFP+, indicating high STAT5A expression 
levels (Figure 6A, top right panel). Hence, under conditions where the leukemic cells spread and 
proliferate in the animal, the enforced expression of STAT5A did not confer any selective 
advantage. Treatment with imatinib was initiated with 100 mg/kg once per day by gavage. 
During therapy, PB samples were checked daily by FACS for the presence of leukemic cells. 
Importantly, the “regular” S5alow leukemic cells steadily declined under imatinib therapy. In 
contrast, the S5ahigh cells remained unaffected and steadily increased (Figure 6B). Nine days after 
treatment initiation, the animals had to be sacrificed because they displayed signs of sickness 
with pronounced weight loss and hind leg ataxia. Pathological analysis revealed that the mice 
suffered from a leukemia densely infiltrating spleen, BM and lymph nodes. FACS analysis showed 
that the leukemic cells consisted nearly exclusively of GFP+ S5ahigh cells (Figure 6B, right panel). 
This was observed in all mice analyzed (n = 6; Figure 6C). In contrast, no selection of S5ahigh cells 
was detected in untreated animals (Figure S5A). Interestingly, we did not only see a selection of 
S5ahigh cells over S5alow cells, but also a selection process within the S5ahigh population with an 
enrichment of the brightest GFP+ S5ahigh cells indicating very high levels of STAT5A protein. The 
GFP fluorescence intensity correlates with the amount of ectopically expressed STAT5A (Figure 
S5B). We observed a 46 fold higher GFP-mean-fluorescence intensity (GFP-MFI) in the S5ahigh 
population compared to the GFP-negative cells which remained constant during the progression 
of the leukemia before imatinib treatment (Figure 6D, top and middle panel). However, 9 days 
after imatinib-treatment the GFP-MFI value directly indicating STAT5A expression had 
significantly increased from 46-fold to 97-fold (Figure 6D, bottom panel, summarized in Figure 
S5C). Next, we questioned if CML cells derived from the murine transplant do have high pSTAT5 
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levels despite the continuous presence of imatinib. As depicted in Figure 6E, S5ahigh leukemic 
cells that evolved in the presence of imatinib displayed pSTAT5 levels that were only slightly 
reduced compared to untreated cells in vitro.  
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METHODS 
Mice 
Stat5a/bnull/+, Stat5fl/+, Stat3fl/fl, Mx1Cre (all mixed C57BL/6J x Sv129), Stat1-/- (C57BL/6J), Cre ERt2 
(FVB/NJ) and NOD.CB17-Prkdc^scid/NCrHsd (NOD/SCID, Harlan Laboratories) mice were 
maintained at the Biomedical Research Institute (Medical University of Vienna) and genotyped 
as described previously.26 NOD/SCID mice were used for leukemia engraftment and imatinib in 
vivo studies. All animal experiments were carried out in accordance with protocols approved by 
Austrian law. 
 
Tissue culture conditions, infections, and in vitro imatinib sensibility assays 
Tissue culture conditions, virus preparation, infection of fetal liver cells with viral supernatant 
from A010 cells or gp + E86 producer cell lines and establishment of cell lines was described 
previously.22  
 
Immunoblotting and EMSA  
Immunoblots and EMSA on the β-casein promoter were carried out as described previously.22,27 
Membranes were probed with antibodies directed against Stat1 (sc-592X), Stat3 (sc-482X), 
STAT5A/B (sc-835X), CDK2 (sc-163), CDK4 (sc-260), c-ABL, (sc-23, all purchased from Santa Cruz), 
-Actin (A5441) and α-Tubulin  (T9026, both Sigma). Antisera against STAT5A and STAT5B have 
been described previously.28 
 
Plasmids 
p210BCR-ABL1, the construct of wild type Stat5a, the Stat5a mutants cS5F, S5a∆N 29, S5a∆749 27, 
S5aEE/AA, S5aY/F 30, and the Stat5b mutant S5b1*6 31 were expressed in the retroviral vector 
pMSCV-IRES-eGFP. V-Abl and p185BCR-ABL1 were cloned into a pMSCV backbone. Ecotropic, 
replication incompetent gp + E86 producers were generated and selected for high virus titer 
production by FACS as described previously.29,32 
 
Imatinib treatment of p210BCR-ABL1-IRES-GFP infected bone marrow 
For imatinib-sensitivity studies of p210Bcr-Abl1+ cells, two different approaches were used. (i) Bone 
marrow cells derived from Stat5+/+ or Stat5null/+ mice were co-cultivated on p210Bcr-Abl1 retroviral 
producer cells for 48 hours in the presence of StemPro-34 serum-free medium (Life 
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Technologies) supplemented with IL-3 [10 ng/ml], IL-6 [5 ng/ml], GM-CSF [1 ng/ml], FLT3-ligand 
[20 ng/ml], IGF-1 [40 ng/ml] SCF [100 ng/ml], Dexamethasone and polybrene [7 µg/ml]. Three 
days after infection, StemPro medium was replaced with cytokine-free RPMI supplemented with 
10% FCS, 1% penicillin/streptomycin and 0.1% β-mercaptoethanol. Five days after StemPro 
medium deprivation, cells were treated with imatinib for 48 hours and analyzed via FACS for GFP 
and MAC-1 expression. (ii) Bone marrow cells derived from Stat5fl/+ Rosa Cre-ERt2 and Stat5+/+ 
Rosa Cre-ERt2 mice were co-cultivated on p210Bcr-Abl1
 
retroviral producer cells for 48 hours in the 
presence of IL-3 [25 ng/ml], IL-6 [50 ng/ml], SCF [50 ng/ml] and polybrene [7 µg/ml] and injected 
via the tail vein into lethally irradiated (10 Gy) wt recipients (1 x 10
6 
cells/mouse). After disease 
onset, the mice were sacrificed and leukemic cells isolated from bone marrow and blood. After 
two weeks of culture time in RPMI complete, growth factor independent leukemic cells were 
analyzed for expression of SCA-1 and c-KIT via FACS. For expression of CRE and deletion of the 
floxed Stat5 allele, cell lines were treated with 1µM tamoxifen-OH. To test for TKI-sensitivity, 
cells were treated with imatinib for 24 hours and percentage PI positive cells were analyzed.   
 
Primary patient samples 
Primary cells were obtained from patients treated at the General Hospital, Vienna, Austria. Cells 
were obtained from patients with CML (n = 36) or secondary AML (n = 2) at routine blood and 
bone marrow examinations after informed consent was given. Peripheral blood and bone 
marrow mononuclear cells (MNC) were isolated using Ficoll. Samples were analyzed for BCR-
ABL1 mutations (complete list of analyzed mutations see Figure S4A) and BCR-ABL1 mRNA level 
according to the international standard protocol. Use of human samples was approved by the 
Ethical Committee of the Medical University of Vienna and is in compliance with Austrian 
legislation.  
 
Immunocytochemistry was performed as described in 33 
 
Statistics 
Two-tailed Student’s t tests were used for statistical analysis. Difference was considered 
statistically significant when P < 0.05. The data are represented as mean ± SD of the number of 
the determinations and were analyzed by Graph Pad® software (San Diego, CA).  
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Figure 1. Prolonged culture times of v-Abl
+
 lymphoid cells correlate with increased STAT5 protein level 
and decreased imatinib sensitivity. (A) Cell counts of LTCs (n = 4) and STCs (n = 6) treated with 100 nM 
imatinib. (B) Representative colony forming assays of LTCs and STCs in growth-factor free methylcellulose 
without and supplemented with 200 nM imatinib.  Pictures of colonies were taken after 14 days (LTCs) and 
21 days (STCs). (C) Dose response curves determined by [
3
H]-thymidine incorporation of LTCs (n = 6) and 
STCs (n = 4) treated with imatinib for 24 hours. Control values in the absence of imatinib were set to 100%. 
(D) Immunoblot analysis of STCs and LTCs for StTAT transcription factors and v-ABL. (A, C: Error bars 
represent mean ± SD. *** P < 0.001). 
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Figure 2. Stat5
null/+
 cells depending on p210
BCR-ABL1
or v-ABL are highly susceptible to imatinib-induced 
apoptosis. (A) BM derived from Stat5
null/+
 (n = 4) and Stat5
+/+
 (n = 6) mice were infected with a retrovirus 
encoding for p210
BCR-ABL1
-IRES-GFP and subsequently treated for 48 hours with increasing dosages of 
imatinib as indicated. Percentages of BCR-ABL1
+
/GFP
+
 cells were analyzed via FACS to evaluate differences 
in imatinib response. Stat5
null/+
 cells reacted significantly more sensitive on imatinib treatment compared 
to Stat5
+/+
 cells. Depicted is one representative FACS-profile. (B) Summary of all experimets described in 
(A). (C) Immunoblot analysis of STAT5A/B and v-ABL protein expression in Stat5
null/+
 and Stat5
+/+
 cells. (D) 
Dose response curves determined by [
3
H]-thymidine incorporation of v-ABL transformed Stat5
null/+
 and 
Stat5
+/+
 cells treated with imatinib for 24 hours (n = 4/genotype). (E) Summary of colony forming assays of 
v-Abl
+
 Stat5
null/+
 and Stat5
+/+
 cells grown for 21 days in growth-factor free methylcellulose enriched with 10 
or 100 nM imatinib (n = 3/genotype). (F,G) Annexin V stained v-ABL transformed Stat5
null/+
 and Stat5
+/+
 
cells challenged with 100 nM imatinib for 24 hours (right, n = 3/genotype). One representative FACS 
profile is depicted in panel G. (Data are means ± SD, * P < 0.05, ** P < 0.001). 
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Figure 3. Enhanced STAT5A expression renders cells less susceptible to imatinib-induced apoptosis. (A) 
FACS profiles of v-Abl
+
 cells ectopically expressing STAT5A and GFP (top profile) and vector control cells 
expressing only GFP (bottom profile) treated 24 hours with imatinib. The percentage of GFP
+
 cells and the 
dosage of imatinib administered are indicated. (B, C) Summary of the experiment depicted in panel A 
repeated with 10 individual v-Abl
+
 (B) and 5 individual p185
BCR-ABL1+ 
(C) cell lines. (D) FACS analysis for PI-
uptake of v-Abl
+
 cell lines sorted for Stat5a-IRES-eGFP expressing- (S5a
high
) and control (S5a
low
) cells 
treated imatinib for 48 hours (n = 3/group). STAT5A/B expression levels were determined by intracellular 
FACS staining and are depicted in the insert. (E) Representative cytospins of S5a
high
 and S5a
low
 cells 48 
hours after imatinib treatment. (F) v-ABL transformed STCs were infected with pMSCV-Stat5a-IRES-eGFP 
and treated with imatinib, dasatinib and nilotinib. The experiment was performed as outlined in Figure 3A. 
The summary of three individually performed experiments is depicted. (G) [
3
H]-thymidine incorporation 
assay of Ba/F3 p210
BCR-ABL1
 cells harboring a doxycycline inducible dominant negative STAT5 (S5a
∆749
). [
3
H]-
thymidine uptake was measured 48 hours after induction of S5a
∆749
 expression and 24 hours after TKI 
treatment.  
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Figure 4. Survival of imatinib treated v-Abl
+
 cells depends on the phosphorylation-status of STAT5. (A) 
FACS profiles of cells infected with pMSCV-Stat5a-IRES-eGFP retrovirus before (left histogram) and after 
sort for GFP (middle histograms). Tyrosine phosphorylated STAT5 is depicted in the right histograms. The 
right panel depicts an EMSA of sorted GFP
+
 (S5a
high
) and GFP
-
 (S5a
low
) cells for STAT5. Stat5
null/null
 MEFs 
were used as negative control and Ba/F3 stimulated with IL-3 were used as positive control. (B) RT-PCR of 
S5a
high
 and S5a
low
 cells before and after treatment with 100 nM dasatinib for 3 hours. Results were 
normalized by Gapdh mRNA expression. The fold change compared to untreated S5a
low
 cell mRNA levels is 
shown (n = 3/group). (C) Scheme of murine wild type and mutant STAT5A variants. Mutants lacking the 
tyrosine phosphorylation (pY) site or having impaired DNA-binding (DB) are indicated by either (+) or (-). 
(D) V-Abl
+
 cell lines expressing STAT5A, STAT5A mutants or vector control along with GFP 24 hours after 
imatinib administration. The fold increase of GFP expressing cells is shown. Error bars represent means ± 
SD. *** P < 0.001 for a dosage of 1000 nM imatinib (n ≥ 4/group). (E) Upper Panel: intracellular pSTAT5 
staining of S5a
low
 and S5a
high
 cells 24 hours after imatinib treatment as indicated. The dashed line displays 
the predicted threshold of pSTAT5 level essential for survival. Lower panel: FACS-analysis for PI-uptake 72 
hours after imatinib treatment as indicated. Percentages of PI-positive cells are shown.  
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Figure 5. Increased STAT5 expression during disease progression and under imatinib treatment in 
human CML-patients. (A) RT-PCR of human STAT5A mRNA transcripts of BM derived from healthy control 
patients (n = 3), PB derived from untreated CML patients in CP (n = 13), AP (n = 7) and relapsed imatinib-
resistant patients (n = 6 for CP, one in AP and one in BC). CML phase, kind of relaps (C, cytogenetic; H, 
hematologic; M, molecular), BCR-ABL1 mutations, IS-value for BCR-ABL1 mRNA level and fold change 
STAT5A mRNA levels compared to mean STAT5A mRNA level of imatinib sensitive CP samples are 
indicated. Each bar represents data derived from an individual patient. (B) STAT5A/B immunoblot of BM 
derived from a healthy patient (control BM) and PB derived from CML diseased patients in CP (n = 6), AP 
(n = 3) and imatinib-resistant CP (n = 3). Each lane represents an individual patient. (C) Expression of 
pSTAT5 in primary CML cells. Mononuclear BM cells from three CML patients, one in CP (upper image), 
one in AP (middle image), and one in BC (C, lower image) were spun on cytospin slides and stained with 
anti-pSTAT5 antibody AX1. Subsets of CML cells in AP and BC were found to stain positive for pSTAT5, 
whereas fewer cells expressed pSTAT5 in CP. Representative examples are depicted. (D) RT-PCR for 
STAT5A and STAT5B of control BM (n = 5) and PB derived from patients in BCR-ABL1-negative BC (n = 2) or 
secondary AML (n = 2).   
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Figure 6. Treatment of leukemic mice with imatinib selects for STAT5A overexpressing cells. (A) Top 
panel, FACS analysis of CD19 and GFP from PB derived cells of a healthy NOD/SCID mouse (left panel), 
freshly established stable v-Abl
+ 
cells infected with pMSCV-eGFP based retrovirus encoding for murine 
STAT5A showing 1% infection efficiency (middle panel) and blood derived cells from a NOD/SCID mouse 13 
days after injection of the v-Abl
+
 cells (right panel). (B) FACS analysis of PB, lymph nodes (LN), spleen (SP) 
and BM after imatinib treatment by gavage [100 mg/kg/day]. Percentage of CD19
+
/GFP
-
 (blue) and 
CD19
+
/GFP
+
 (red) cells is shown. (C) Summary of the in vivo experiment depicted in panel A and panel B for 
a total of 6 mice. Error bars represent means ± SD. (D) Representative FACS profile of v-Abl
+
 cells before 
injection (top panel), 13 days after injection (middle panel) and 9 days after in vivo imatinib treatment 
(bottom panel). Fold difference of GFP-mean fluorescence intensity of GFP
+
 (S5a
high
) to GFP
-
 (S5a
low
) cells 
are indicated. (E) pSTAT5 level of ex vivo derived S5a
high
 cells 9 days after in vivo imatinib [100 mg/kg/day] 
treatment (lower histograms) and in vitro control S5a
high
 cells before and after 24 hours after imatinib 
[1000 nM] addition (upper histograms). 
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3.4 C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting 
methylation of the 5’ region of Cdk6. 
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ABSTRACT 
The transcription factor c-JUN and its upstream kinase JNK1 have been implicated in BCR-ABL 
induced leukemogenesis. JNK1 has been shown to regulate BCL2 expression thereby altering 
leukemogenesis, but the impact of c-JUN remained unclear. In this study we show that JNK1 and 
c-JUN promote leukemogenesis via separate pathways, since lack of c-JUN impairs proliferation 
of p185BCR-ABL transformed cells without affecting viability. The decreased proliferation of c-Jun 
cells is associated with the loss of cyclin dependent kinase 6 (CDK6) expression. In c-Jun cells 
CDK6 expression becomes down-regulated upon BCR-ABL induced transformation which 
correlates with CpG island methylation within the 5´ region of Cdk6. We verified the impact of 
Cdk6 deficiency by using Cdk6-/- mice that developed BCR-ABL induced B-lymphoid leukemia with 
significantly increased latency and an attenuated disease phenotype. In addition we show that 
re-expression of CDK6 in BCR-ABL transformed c-Jun cells reconstitutes proliferation and 
tumor formation in Nu/Nu mice. In summary, our study reveals a novel function for the AP-1 
transcription factor c-JUN in leukemogenesis by antagonizing promoter methylation. Moreover, 
we identify CDK6 as relevant and critical target of AP-1 regulated DNA methylation upon BCR-
ABL induced transformation, thereby accelerating leukemogenesis.    
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INTRODUCTION 
Activating protein 1 (AP-1) functions as a dimeric transcription factor in important cellular 
processes such as proliferation, differentiation and apoptosis.1-3 This wide range of different 
roles is made possible by variable compositions of many homo-and heterodimers which are 
formed by the JUN, FOS, ATF and MAF proteins that comprise the AP-1 transcription factors.4,5 
C-JUN was originally identified as the normal cellular counterpart of the avian sarcoma JUN 
oncoprotein (v-JUN). Mouse model experiments revealed the essential role of c-JUN for 
development. C-Jun-/- mice die at embryonic day 12.5 to 13.5 displaying multiple defects in liver, 
heart and neural crest.6,7 C-JUN was shown to transform cells in culture6-8 and is commonly 
expressed at high levels in human malignancies.9,10 High levels of c-JUN have been described in a 
large fraction of human melanoma samples11, liposarcomas12, lymphomas13 and are important 
players in skin and liver tumorigenesis.14,15 The tumor promoting roles of c-JUN have been 
attributed to growth accelerating effects via the regulation of CYCLIN expression16 or attributed 
to anti-apoptotic properties. In hepatocytes, c-JUN antagonizes the function of the tumor 
suppressor protein p53 and protects transformed hepatocytes from cell death.17 In T-cells, c-JUN 
is involved in the expression of FAS ligand (FASL) triggering apoptosis through the FAS receptor.18 
In BCR-ABL driven leukemogenesis both, c-JUN and its upstream regulator JNK1 have been 
described as tumor promoters.19-22 For JNK1-/- transformed cells, the underlying mechanism has 
been elucidated: JNK1-/- cells express severely reduced levels of the anti-apoptotic protein BCL2 
which leads to a significantly delayed leukemogenesis in BCR-ABL transformed cells.21 However, 
it remained unclear whether this effect was mediated via c-JUN dependent phosphorylation. 
In this report we describe a novel mechanism how AP-1 transcription factors modulate 
tumorigenesis. In B-lymphoid cells c-JUN counteracts the BCR-ABL induced DNA methylation 
within the 5’ region of Cdk6. Thereby c-JUN prevents the BCR-ABL induced silencing of the CDK6 
gene. A lack or down regulation of CDK6 is associated with a pronounced increase of disease 
latency as verified by the use of Cdk6-/- mice. Our study thereby reveals primary insights in the 
role of AP-1 transcription factors for oncogene induced gene-silencing. Moreover, we provide 
the first conclusive evidence for a non-redundant tumor promoting role of CDK6 in lymphoid 
malignancies. 
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MATERIALS AND METHODS 
Mice and infection of neonatal mice with Ab-MuLV 
c-Junfl/fl 27, CD19Cre/+ mice 28, Jnk1-/- 29, c-JunAA/AA 30, p53-/- 31, Cdk6-/- 32, Nu/Nu and Rag2-/- mice 33, 
were described previously. Animal experiments were performed in accordance with protocols 
approved by the Animal Welfare Committee (MUW). Newborn mice were injected 
intraperitoneally with 50µL of replication-incompetent ecotropic retrovirus encoding for Ab-
MuLV.34 Sick mice were sacrificed. Peripheral blood, lymphoid and hematopoietic organs were 
analysed for leukemic cells by FACS and by histopathology.  
 
Cell culture, infection of fetal liver cells and expression vectors 
Tissue culture conditions, virus preparation, infections, transformation-assays and establishment 
of cell-lines were performed as described previously.13,34,35 The expression vectors used for the 
experiments were pMSCV-puro, pMSCV-Cdk6-puro and pMSCV-Bcl2-puro.  
 
Transplantation of tumor cells into RAG2-/- and Nu/Nu mice  
For tail vein injections, a defined cell number from independently derived pMSCV- p185BCR-ABL-
IRES-GFP-transformed cell lines were injected into Rag2-/- mice. For subcutaneous injections, 1 x 
106 cells were injected into Nu/Nu mice. Sick mice were killed and analyzed for spleen weights, 
white blood cell counts and the presence of leukemic cells in bone marrow, spleen, liver and 
blood by FACS analysis.  
 
[3H]-thymidine incorporation 
5 x 104 cells were plated in triplets in 96-well plates and [3H]-thymidine (0.1µCi/well [MBq/well]) 
was added. After 12h incubation, analysis was performed with Ultima Gold MV scintillation fluid 
(Packard Instruments) by a scintillation counter. 
 
Flow cytometric analysis 
FACS analysis was done by a FACSCanto flow cytometer using FACSDiva software. B-cell 
development staining: We used different antibodies to determine the specific B-lineage 
maturation stages: B220 (CD45R; RA3-6B2), CD43 (1B11), CD19 (1D3), BP-1 (6C3), IgM (R6-60.2) 
and IgDb (IgH-5b; 217-170) (all BD Pharmingen). 
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Cell cycle analysis: 5 x 106 cells were stained with PI (50 μg/ml) in a hypotonic lysis solution 
(0.1% sodium citrate, 0.1% triton X-100, 100 μg/ml RNAse) and incubated at 37°C for 30 
minutes.  
 
Protein analysis and Western blotting 
Cells were lysed in a buffer containing protease and phosphatase inhibitors (50 mMHepes, pH 
7.5, 0.1% Tween-20, 150 mM NaCl, 1 mM EDTA, 20 mM β-glycero-phosphate,0.1 mM sodium 
vanadate, 1 mM sodium fluoride, 10 µg/ml aprotinin, leupeptin and 1 mMPMSF, respectively). 
Protein concentrations were determined using a BCA-kit (Pierce). Proteins (100µg) were 
separated on 12% SDS-polyacrylamide gels and transferred onto Immobilon membranes. 
Membranes were probed with antibodies directed against CDK6 (C8343), β-ACTIN (A-4700) 
(Sigma Aldrich Inc.), c-JUN (sc-1694x), p53 (sc-6243), BCL2 (sc-7382), CDK4 (sc-260), p21 (sc-471), 
p27 (sc-1641), p15 (sc-612), p16 (sc-1207) (Santa Cruz Biotechnologies Inc.). Immunoreactive 
bands were visualized by chemiluminescent detection (ECL detection kit; Amersham). Treatment 
with Aza-dC (Sigma Aldrich Inc.): Cells were seaded in 1 μM Aza-dC. After 12, 24, 36 and 48 
hours incubation western blot analysis was performed. 
 
RNA-isolation and Real time-PCR analysis 
RNA was isolated using TriZol (Invitrogen). First-strand cDNA-synthesis and PCR-amplification 
were performed using a reverse transcriptase–polymerase chain reaction (RT-PCR) kit (GeneAmp 
RNAPCRkit; Applied Biosystems) according to the manufacturer. Real time PCR was performed 
on an Eppendorf RealPlex cycler using RealMasterMix (Eppendorf) and SYBR Green as 
described before 
36
. The following primer pairs were used: Gapdh: 5`-
AGAAGGTGGTGAAGCAGGCATC-3` and 5`-CGGCATCGAAGGTGGAAGAGTG-3` and 
Cdk6: 5’-GCTTCGTGGCTCTGAAGCGCG-3’ and 5’-TGGTTTCTGTGGGTACGCCGG-3’. 
Real time-PCR for Dnmt: 1µg of total RNA was used for cDNA preparation using the Omniscript 
RT Kit (Qiagen, Hilden, Germany). Real-Time RT-PCR of Dnmt1, Dnmt3a and Dnmt3b was 
performed using Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA) as 
recommended by the manufacturer. Gapdh was used as reference gene for normalization of RT-
PCR data. 
 
Nucleic acid isolation, methylation-specific PCR (MSP) and bisulfite genomic sequencing 
Genomic DNA was isolated from murine c-Junfl/fl and c-JunΔ/Δ cell lines by digestion with 
Proteinase K, followed by standard phenol-chloroform extraction and ethanol precipitation as 
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reported previously (Sambrook, Fritsch et al. 2. Edition). Afterwards, 1μg of genomic DNA was 
used for chemical modification by sodium bisulfite using the Epitect kit (Qiagen, Hilden, 
Germany). The methylation status of the region 5´ to the coding sequence of Cdk6 was analyzed 
by methylation-specific PCR (MSP). In brief, we performed a search for CpG islands in the 5’ 
region of Cdk6 (ENSMUSG00000040274, www.ensembl.org, release 52) using the CpGplot tool 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/index.html) and found a CpG island which is 
located at -187 bp to +279 bp relative to the transcription start site of Cdk6 (Figure 5A). MSP 
primers were designed to amplify a region at -40 bp to +193 bp relative to the transcription start 
site of Cdk6. MSP primers sequences are as follows: Cdk6m-fwd, 5´-
TAGTTCGGCGGTCGCGAGTTCG-3´, Cdk6m-rev, 5´-CGCACGCGCTTCAAAACCACG-3´, Cdk6u-fwd, 5´-
TAGTTTGGTGGTTGTGAGTTTG-3´ and Cdk6u-rev, 5´-TCACACACACTTCAAAACCACA-3´. The PCR 
was performed using following conditions: initial denaturation for 12 minutes at 95°C followed 
by 38 cycles of denaturation for 30 seconds at 95°C, annealing for 40 seconds at 64°C and 
extension for 30 seconds at 72°C with a final extension for 7 minutes at 72°C. MSP products 
were separated in 2% agarose gels stained with GelRedTM (Biotium, Hayward, CA, USA) and 
visualized under UV spectrophotometry. DNA extracted from murine cell lines was treated with 
Sss1 CpG methylase (New England Biolabs, Beverly, MA, USA) and used as a positive control for 
methylated alleles. Water blanks were used as negative controls. For bisulfite genomic 
sequencing PCR primers were designed to anneal at both methylated and unmethylated bisulfite 
converted DNA. Primer sequences are available upon request. The PCR products were 
sequenced using the 3100 Genetic Analyzer (PE Applied Biosystems). 
 
Statistical Analysis 
Data are reported as mean values ± SEM, biochemical experiments were performed in triplicates 
and a minimum of three independent experiments were evaluated. Differences were assessed 
for statistical significance by an unpaired two-tailed t test or the log rank test (for Kaplan-Meier 
plots). 
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RESULTS 
JNK1 and c-JUN are involved in BCR-ABL induced transformation  
The AP-1 upstream kinase JNK1, as well as the AP-1 transcription factor c-JUN have been 
implicated in BCR-ABL driven leukemogenesis.19,21,22 We confirmed these previous observations 
by performing colony formation assays in growth factor free methylcellulose. Fetal liver cells 
were prepared from Jnk1-/- and c-Junfl/flCD19Cre/+ embryos and appropriate controls and infected 
with a retrovirus encoding p185BCR-ABL (pMSCV- p185BCR-ABL -IRES-GFP). As expected, a significant 
reduction of growth factor independent colony numbers was detected when Jnk1-/- or c-
Junfl/flCD19Cre/+ hematopoietic cells were used (Figure 1A and 1B). Following transformation, 
CD19+/CD43+ leukemic cell lines were generated from all cultures. The lack of Jnk1 has been 
reported to be associated with an increased disease latency.21 In order to study tumor cell 
intrinsic characteristics in vivo, we made use of Rag2-/- mice. The lack of lymphoid cells in Rag2-/- 
mice makes them particularly suitable to study lymphoid malignancies. Upon injection of c-
Junfl/flCD19Cre/+ (c-Jun and c-Junfl/f stable cell lines via tail vein the mice developed leukemia 
with infiltrations of leukemic cells in bone marrow, spleen, liver and lymph nodes (data not 
shown). As summarized in Figure 1C, leukemia evolved with a significantly enhanced latency in 
mice that had received c-Juncells. The signs of disease were attenuated as evident from the 
reduced spleen weight of mice suffering from a c-Jun deficient leukemia (Figure 1D). 
 
JNK1 and c-JUN act via different pathways in promoting BCR-ABL induced leukemia 
The lack of Jnk1 in BCR-ABL transformed cells was reported to decrease BCL2 expression, which 
was verified as the major cause for the reduced malignancy of Jnk1-/- cells upon BCR-ABL 
transformation. Transgenic expression of BCL2 in these cells rescued apoptosis and restored 
tumors.21 Indeed, BCL2 protein expression was also reduced in c-Jun
Δ/Δ cells when compared to c-
Junfl/fl control cells (Figure 2A). To explore whether the reduction in BCL2 expression accounts for 
a delayed tumorigenesis in c-Juncells, we expressed BCL2, encoded by a retrovirus, in BCR-ABL 
transformed c-Jun and c-Junfl/fl cells (Figure 2B, lower panel). Leukemia formation was then 
investigated by injecting these cells into Rag2-/- animals via the tail vein. Surprisingly, disease 
latency was unaffected irrespective whether we injected c-Jun cells or c-Junfl/fl cells expressing 
low or high levels of BCL2 (Figure 2B, upper panel and S1A). To further investigate whether JNK1 
and c-JUN act in a signaling cascade independent of BCL2 we made use of c-Jun
AA/AA mice 
harbouring point mutations at the critical serine sites subjected to phosphorylation by JNK. 
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Newborn c-JunAA/AA mice and appropriate controls were infected intraperitoneally with the 
replication deficient retrovirus Ab-MuLV encoding v-Abl. As additional control, we used c-
Junfl/flCD19Cre/+ and compared them to c-Junfl/fl mice. Ab-MuLV infects B-lymphoid precursors and 
induces a slowly evolving pro-B-cell leukemia in mice. As depicted in Figure 2C, c-Junfl/flCD19Cre/+ 
developed leukemia with a significantly enhanced latency compared to c-Junfl/fl mice, which is 
clearly in line with the tumor promoting effect of c-JUN. However, no effect was observed when 
we compared c-JunAA/AA mice to control animals (Figure 2D). The slight difference in latency 
between the control mice in these two experiments are caused by minor background differences 
of the animals. In line, we failed to detect any alteration in the outgrowth of c-JunAA/AA and 
control p185BCR-ABL transformed cell lines (data not shown). These data indicate that JNK1 and c-
JUN promote BCR-ABL driven tumorigenesis independently by using different mechanisms.  
 
c-Jun deficient cells show a proliferative defect 
AP-1 members regulate survival, differentiation and proliferation.15 Since the enforced 
expression of BCL2 did not accelerate leukemogenesis in c-Jun
 cells, we next investigated cell 
growth of BCR-ABL transformed c-Jun cells. Six individually derived stable cell lines lacking c-
Jun and corresponding control cell lines were generated. [3H]-thymidine incorporation assays as 
well as growth curves showed a significant difference in the proliferation of c-Jun and c-Junfl/fl 
cells. C-Jun cells expanded significantly slower (Figure 3A and 3B).  This was also evident from 
the DNA content of asynchronously proliferating cells: c-Jun cells showed a significantly 
increased proportion of cells in G1-phase and a decreased proportion in S-phase (Figure 3C). In 
order to monitor tumor growth in vivo, we made use of Nu/Nu mice. Tumor cells were injected 
subcutaneously to allow monitoring of tumor growth. These in vivo experiments recapitulated 
the in vitro observations. C-Jun tumors evolved significantly slower in Nu/Nu mice. The 
experiment was terminated after 10 days when the first tumor reached 1 cm diameter in size. At 
that time point, the weight of the c-Jun tumors compared to the c-Junfl/fl tumors was 
significantly smaller (Figure 3D). In hepatocytes, c-JUN accelerates tumor formation by 
antagonizing the pro-apoptotic activity of p53.17 In order to investigate whether this mechanism 
occurs in B-lymphoid leukemogenesis, we crossed c-Junfl/fl and c-Junfl/flCD19Cre/+ mice with p53-/- 
mice and subsequently assessed leukemia formation. Newborn c-Junfl/flp53-/- and c-
Junfl/flCD19Cre/+p53-/- mice were challenged with Ab-MuLV. As depicted in Figure 2E, p53 
deficiency was not capable to counteract or change the prolongation of disease latency induced 
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by the loss of c-Jun. These experiments point out the involvement of c-JUN in growth control in 
p185BCR-ABL positive tumor cells. 
 
Transformed c-Jun cells down-regulate the expression of the cell cycle kinase CDK6 
When we analyzed several cell cycle components (Figure 4A) we found that the loss of c-JUN 
was associated with the down-regulation of CDK6 expression in leukemic B-cells whereas other 
cell cycle components showed no consistent alterations. Loss of CDK6 was restricted to stable c-
Jun cell lines and not observed in p185BCR-ABL transformed c-JunAA/AA cells, supporting the 
independence of JNK phosphorylation (Figure 4B). The protein expression of CDK6 steadily 
declined after 2, 4, 6 and 8 weeks of the initial transformation event by retroviral infection with 
p185BCR-ABL in c-Jun cells (Figure 4C). This constant protein reduction correlated with a 
decrease in the proliferative capacity of the cells (Figure 4D). It is important to mention that 
already after 2 weeks, the cell cultures consisted of more than 95% GFP+ and so BCR-ABL+ cells. A 
decreasing contamination with non transformed cells can therefore be ruled out. qPCR 
experiments revealed that the reduction of CDK6 protein was accompanied by a loss of Cdk6 
mRNA (Figure 4E).  
 
The lack of c-JUN leads to the methylation within the 5’ region of Cdk6 in p185BCR-ABL 
transformed cells 
To determine whether epigenetic changes may be responsible for the down-regulation of CDK6 
in p185BCR-ABL transformed cells we developed assays for DNA methylation analysis of the 5’ 
region of the Cdk6 gene. Using a CpG island search tool we identified a 1000bp long CpG island 
comprising the transcription start site of Cdk6 (Figure 4A). This region was used as target for 
methylation-specific PCR (MSP) analysis and bisulfite genomic sequencing. As analyzed by MSP, 
the time dependent reduction of Cdk6 mRNA co-incided with DNA methylation within the 5’ 
region of Cdk6 (Figure 5B, upper panel). While Cdk6 methylation was detected in all stable cell 
lines lacking c-JUN, the c-Junfl/fl cells were not methylated for this gene (Figure 5B, lower level). 
Results obtained by MSP were confirmed by bisulfite genomic sequencing of the Cdk6 5´ region 
in c-Jun and c-Junfl/fl cells (Figure 5C). Further confirmation was obtained when we treated the 
BCR-ABL transformed c-Jun cells with the demethylating agent 5-aza-2´-deoxycytidine (Aza-
dC) for 48 hours. As expected, Aza-dC induced demethylation of DNA resulted in re-expression of 
CDK6 already 12 hours after treatment (Figure 5D). True to form, most of the cells turn into 
G0/G1-phase (Figure S2A) and began to die 12 hours after Aza-dC addition (Figure 5E). Analyzing 
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the mRNA levels of DNA methyltransferases (Dnmt1, Dnmt3a, Dnmt3b) in c-Jun and c-Junfl/fl 
cells by real-time PCR showed a significant higher amount of Dnmt3b mRNA in c-Juncells 
compared to c-Junfl/fl cells (Figure 5F).  
 
Loss of CDK6 in BCR-ABL transformed cells recapitulates the phenotype of c-Jun deficiency 
We next asked whether the loss of CDK6 accounts for the reduced proliferation of BCR-ABL 
transformed c-Jun cells and provokes the increased disease latency. To study the contribution 
of CDK6 to BCR-ABL induced tumor formation we employed Cdk6-/- animals. Since no 
information on a potential role of CDK6 in B-lymphoid development was available, we first 
monitored the emergence of individual defined B-cell stages. As depicted in Figure 6A, Cdk6-/- 
mice had significantly elevated levels of pre-pro B-cells. The total cell number of peripheral 
mature B-cells was unaltered, indicating that this partial block was compensated in vivo. Mature 
Cdk6-/- B-lymphocytes responded equally well to mitogenic stimuli as compared to control cells 
(Figure S3A). We next transformed fetal liver derived Cdk6-/- cells and wild type controls with a 
pMSCV-p185BCR-ABL-IRES-GFP retrovirus. GFP+/CD43+/CD19+/B220+ colonies and cell lines were 
obtained with equal frequencies (Figure S3B). However a significant difference became obvious 
in a [3H]-thymidine incorporation assay; a decreased proliferation was also documented by 
growth curves (Figure 6B and C). These data point towards an essential non-redundant role for 
CDK6 in the transformed B-cells. This is in contrast to the observation in non- transformed 
mature B-cells, where the lack of CDK6 did not impair proliferation (Figure S3A).  
To assess tumor formation in vivo we injected a replication-incompetent retrovirus encoding Ab-
MuLV in newborn mice thereby inducing a slowly emerging lymphoid leukemia. The outcome of 
the experiment is summarized in Figure 6D: strikingly, Cdk6-/- animals developed disease 
significantly later and survived the oncogenic challenge up to five months, whereas all Cdk6+/+ 
and Cdk6+/- mice succumbed to leukemia within ~ 2 months. A slightly decreased infiltration of 
spleens with leukemic cells was found in Cdk6-/- mice, nevertheless the difference did not meet 
the criteria of being statistically significant (Figure 6E). This experiment highlighted a non-
redundant role of CDK6 as a tumor promoter for p185BCR-ABL-induced B-cell leukemia. In 
summary, these data revealed a non-redundant tumor promoting role for CDK6 in p185BCR-ABL 
driven leukemogenesis. 
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Re-expression of CDK6 reconstitutes proliferation in c-Jun cells 
To define whether the loss of CDK6 accounts for the decreased proliferation and tumor 
formation of BCR-ABL transformed c-Jun cells we re-expressed CDK6, with a pMSCV-Cdk6-puro 
retrovirus in c-Jun cells (Figure 7A). As depicted in Figure 7B, c-Jun cells proliferated 
significantly faster after CDK6 expression compared to control cells that had been infected with 
the empty vector. Additionally, the proportion of these cells in G1- and S-phase showed no 
significant difference compared to c-Junfl/fl (Figure 7C). In line with this, tumor formation in 
Nu/Nu mice was assessed with c-Jun-Cdk6-puro cells compared to c-Jun cells. In this in vivo 
experiment an increased tumor size of c-JunCdk6-puro cells was detected (Figure 7D). We 
concluded that re-expression of CDK6 in c-Jun cells restores proliferation to levels observed in 
wild type control cells and accelerates tumor formation in vivo.  
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DISCUSSION 
In this report we show that the AP-1 transcription factor c-JUN promotes BCR-ABL induced 
leukemogenesis by maintaining the expression of the cell cycle kinase (CDK6). C-JUN is required 
to protect the CpG island in the 5’ regtion of Cdk6 from getting methylated. Thereby we define a 
novel mechanism how AP-1 transcription factors that are commonly up-regulated in 
transformed cells contribute to tumorigenesis. Furthermore we define for the first time a tumor 
promoting role for CDK6 in B-lymphoid leukemogenesis.  
Although c-JUN has unequivocally been enrolled in the regulation of apoptosis during 
tumorigenesis17, these effects have been excluded for BCR-ABL induced B-lymphoid 
leukemogenesis. Neither the enforced expression of BCL2 nor the lack of p53 counteracted or 
influenced the effects on disease latency that occurred in the absence of c-JUN during leukemia 
progression. This opposes the situation in Jnk1-/- cells, where the enforced expression of BCL2 
reconstituted leukemogenesis.21 This also led us to conclude that JNK1 exerts its effects 
independently of c-JUN. Further proof was obtained by investigating BCR-ABL induced 
leukemogenesis in c-JunAA/AA mice that did not display any obvious alterations or phenotypes 
when challenged with the p185BCR-ABL oncogene. How JNK1 regulates BCL2 expression and 
promotes survival, independently of c-JUN, remains to be determined.  
However, we cannot entirely rule out that c-Jun exerts a survival function during the initial 
transformation event. Similar to Jnk1-/-, c-Jun cells gave rise to significantly reduced colony 
numbers when plated in growth factor free methylcellulose. This effect cannot be attributed to 
CDK6 which does not display a reduction in colony numbers in the initial transformation event. 
Obviously transformation induces rewiring of signaling pathways and changes the signaling 
network required for survival and proliferation. Hence, factors that are required within the initial 
transformation process may become irrelevant for tumor cell maintenance. This has been 
recently demonstrated for the transcription factor STAT3.37 In contrast, its close relative STAT5 
comes into a privileged position and is essential for the survival of BCR-ABL+ cells.38 One might 
speculate that initially c-JUN exerts a role in survival which is subsequently taken over by STAT5.  
Interestingly, non transformed B-lymphoid cells lacking c-JUN express regular levels of CDK6. 
Only upon transformation with the BCR-ABL oncogene the 5’ region of Cdk6 becomes 
methylated, if not protected by c-JUN. Thus, our results suggest that methylation of the 5’ region 
of Cdk6 may be prevented by c-JUN. Hundreds of possibly epigenetically silenced genes may 
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exist in individual tumors. While a selection for stochastic events certainly exists and selects for 
dominant tumor clones in individual tumors it is unlikely that all of these events arise in a 
random fashion. The current model suggests that the existence of multiple epigenetically 
silenced genes rather reflects a general program of epigenetic control abnormalities. These early 
epigenetic silencing events could represent primary alterations induced by the initial 
transformation event. Our data support this model since the BCR-ABL induced transformation 
consistently provoked the silencing of the Cdk6 gene by DNA methylation. This BCR-ABL induced 
methylation was only apparent in c-JUN deficient cells, since it is efficiently counteracted by c-
JUN in a wild type background. We envision the Cdk6 promoter being only one among many 
silenced genes due to a general reprogramming that is triggered by the initial BCR-ABL induced 
transformation. Alternatively one might suggest that c-JUN is exclusively required for CDK6 
expression. In the absence of c-JUN Cdk6 transcription comes to a stop which then induces DNA 
methylation. The fact that we found increased mRNA levels of the DNA methyltransferase 
Dnmt1, Dnmt3a and Dnmt3b in BCR-ABL transformed c-Jun cells point at a general mechanism 
not specific for Cdk6. Of interest is the fact that the de novo methyltransferase Dnmt3b was 
significantly high in the absence of c-JUN. The enzymes DNMT3a and DNMT3b, account for the 
somatic methylation pattern during embryogenesis and favour semi- and un-methylated DNA 
substrates.39,40 In contrast DNMT1 specifies on the copying of already existing methylation 
patterns.39,41  
What singles out CDK6 silencing is the fact that CDK6 significantly contributes to the tumor 
promoting role of c-JUN. The reduced growth of BCR-ABL transformed c-Jun cells can be 
largely overridden by the enforced expression of CDK6. This re-expression reconstitutes the 
proliferative ability of the cells and thereby enhances tumor formation in Nu/Nu mice. It is also 
noteworthy that the expression of CDK6 is not only subject to a regulation by c-JUN but also by 
the related protein JUNB. We have recently described that JUNB suppresses the transcription of 
Cdk6 in BCR-ABL transformed cells.35 As a consequence the loss or down regulation of JUNB – as 
observed in human myeloid and B-lymphoid malignancies – provokes an increased CDK6 
expression. In summary a shift of AP-1 composition occurs in B-lymphoid malignancies: c-JUN 
becomes up-regulated whereas JUNB remains constant or gets down-regulated.13 Based on 
these alterations of AP-1 expression pattern one might therefore expect an overall increased 
expression of CDK6 in B-lymphoid malignancies. Indeed, an enhanced CDK6 protein expression 
has been documented in lymphoma and leukemia in people.42-45 In particular, several reports 
documented chromosomal translocations in patients suffering from B-lymphoid malignancies 
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involving CDK6. In these patients, the aberrant and increased expression of CDK6 had been 
proposed to represent a cause and/or driving force for the B-cell disease.46-48 Additionally, a 
recent study describes a down-regulation of the microRNA, hsa-miR-124a, during acute 
lymphoblastic leukemia resulting in an up-regulation of CDK6.49 Nevertheless, it remained 
unclear up to now, whether the enforced expression of CDK6 represents a bystander alteration 
or is indeed a driving force in B-lymphoid leukemogenesis. We now provide first evidence for the 
tumor promoting role since the absence of CDK6 drastically prolonged tumorigenesis in vivo. 
CDK6 advanced the growth of transformed B-lymphoid cells: p185BCR-ABL-induced leukemia was 
significantly delayed in Cdk6-/- mice, the lifespan of the affected animals again nearly doubled. 
Hence, in B-lymphoid malignancies, CDK6 exerts a unique and non-redundant tumor promoting 
role. This is in contrast to non transformed B-cells that are independent from CDK6 for their 
development. CDK6 comes into this privileged position only upon BCR-ABL induced 
transformation where it takes over the dominant role during G1-phase of the cell cycle. It is 
attractive to speculate that this alteration might be the direct consequence of the changed AP-1 
expression profiles and result from the combination of low or missing JUNB combined with 
elevated c-JUN expression. 
In summary we provide first insights into a role for the AP-1 transcription factor as modulators of 
epigenetic reprogramming occurring in transformed cells. Our data reveal a linear axis for c-JUN 
and CDK6 in the regulation of proliferation in transformed B-lymphoid cells. In this scenario 
CDK6 gets into a privileged and unique position and exerts a non redundant tumor promoting 
role. 
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Figure 1 
Figure 1: c-JUN is concerned in p185
BCR-ABL 
induced transformation and leukemogenesis. Colony 
formation assays (CFA) were performed using 1 x 10
6
 A) JNK1
+/-
 and JNK1
-/-
 (n = 8; two-tailed; 49.2 ± 7.9 vs. 
28.9 ± 4.1 colonies/ 10
7
 fetal liver cells, p = 0.0401) and  B) c-Jun
fl/fl 
and c-Jun
fl/fl
CD19
Cre/+
  (n = 6; two-tailed; 
60.5 ± 6.1 vs. 27.3 ± 1.9 colonies/ 10
7
 fetal liver cells, p = 0.0004) fetal liver cells after infection with a 
pMSCV-p185
BCR-ABL
-IRES-GFP retrovirus in growth factor free methylcellulose. C) Transplantation of 1 x 10
5 
c-Jun
fl/fl 
and c-Jun
Δ/Δ 
cells into Rag2
-/-
 mice. 2 independent cell lines per each cell type were injected in 9 
mice (mean survival, 11 vs. 16 days in mice injected with c-Jun
fl/fl 
and c-Jun
Δ/Δ
 cells, respectively; p = 
0.0307). D) Spleen weights of diseased recipient Rag2
-/-
 mice were analyzed (c-Jun
fl/fl 
n = 9 and c-Jun
Δ/Δ 
n = 
9; two-tailed; p = 0.0169).  
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Figure 2 
 
Figure 2: Enforced BCL2 expression doesn’t alter c-JUN deficient leukemogenesis. A) Protein levels of c-
JUN and BCL2 in c-Jun
fl/fl 
and c-Jun
Δ/Δ
 p185
BCR-ABL
-transformed cells. β-ACTIN served as loading control.B) 1 x 
10
5
 leukemic c-Jun
Δ/Δ 
B-cells, transduced either with pMSCV-puro or pMSCV-Bcl2-puro, were injected 
intravenously into Rag2
-/-
 mice. (n = 11 and n = 13, respectively; mean survival, 17 vs. 17.5 days in mice 
injected with c-Jun
Δ/Δ-puro 
and c-Jun
Δ/Δ-Bcl2-puro 
cells; p = 0.3552) (upper panel).Immunoblot analysis showing 
enforced expression of BCL2 upon a pMSCV-Bcl2-puro retrovirus infection in c-Jun
fl/fl 
and c-Jun
Δ/Δ 
cells. β-
ACTIN served as loading control (lower panel).C) Injection of c-Jun
fl/fl 
(n = 11) and c-Jun
fl/fl
CD19
Cre/+
 (n = 7) 
newborn mice with a replication-deficient Ab-MuLV encoding retrovirus resulted in B-lymphoid 
leukemia/lymphoma (mean survival 31 vs. 48 days in c-Jun
fl/fl 
and c-Jun
fl/fl
CD19
Cre/+ 
mice, respectively; p = 
0.0173). D) Injection of c-Jun
fl/fl 
(n = 9) and c-Jun
AA/AA
 (n = 6) newborn mice with a replication-deficient Ab-
MuLV encoding retrovirus resulted in B-lymphoid leukemia/lymphoma (mean survival 52 vs. 73 days in c-
Jun
fl/fl 
and c-Jun
AA/AA
 mice, respectively; p = 0.6168). 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: c-Jun
Δ/Δ
 p185
BCR-ABL
-transformed cell lines demonstrate a proliferative defect. A) [
3
H]-thymidine 
incorporation of fetal liver-derived c-Jun
fl/fl 
(n = 3) and c-Jun
Δ/Δ
 (n = 4; two-tailed; p = 0.0142) p185
BCR-ABL
-
transformed cell lines. B) 1 x 10
5
 p185
BCR-ABL
-transformed c-Jun
fl/fl 
(n = 3) and c-Jun
Δ/Δ
 cells (n = 3) were 
plated and total cell numbers were determined after 48, 96 and 144 hours. C) Cell cycle profiles of c-Jun
fl/fl 
(n = 5) and c-Jun
Δ/Δ
 (n =4) cells (two-tailed; G1-phase: p = 0.0333 and S-phase: p = 0.0173), gated on living 
cells. One representative set of data is depicted. D) Tumor weights of Nu/Nu mice that were 
subcutaneously injected with 1 x 10
6
 c-Jun
fl/fl 
and c-Jun
Δ/Δ
 leukemic cells. 3 independent cell lines per each 
cell type were injected into 9 mice (two-tailed; p = 0.0007). E) Injection of c-Jun
fl/fl
p53
-/-
 (n = 11)
 
and c-
Jun
fl/fl
CD19
Cre/+
p53
-/-
 (n = 7) newborn mice with a replication-deficient Ab-MuLV encoding retrovirus 
resulted in B-lymphoid leukemia/lymphoma (mean survival, 31 vs. 44 days in c-Jun
fl/fl
p53
-/- 
and c-
Jun
fl/fl
CD19
Cre/+
p53
-/- 
mice; p = 0.0213). 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: CDK6 protein levels are down-regulated in c-Jun
Δ/Δ
 p185
BCR-ABL
-transformed cell lines. A) 
Immunoblot analysis for CDK6, CDK4, CDK2, Cyclin D2, Cyclin D3; p16
INK4a
, p15
INK4b
, p21 and p27 and 
protein expression in c-Jun
fl/fl 
and c-Jun
Δ/Δ
 p185
BCR-ABL
-transformed cells. β-ACTIN served as loading control. 
B) Immunoblot analysis for c-JUN and CDK6 protein expression in c-Jun
fl/fl 
and c-Jun
Δ/Δ
 (upper panel) and c-
Jun
fl/fl 
and c-Jun
AA/AA
 (lower panel) p185
BCR-ABL
-transformed cells. β-ACTIN served as loading control. C) C-
JUN and CDK6 protein levels of c-Jun
Δ/Δ
 and c-Jun
fl/fl 
cell lines after 2, 4, 6 and 8 weeks of transformation. 
β-ACTIN served as loading control. One representative set of data is depicted. D) [
3
H]-thymidine 
incorporation of the same cell lines was measured (n = 3; two tailed: c-Jun
fl/fl
 vs. c-Jun
Δ/Δ
 6 weeks, p = 
0.002; c-Jun
fl/fl
 vs. c-Jun
Δ/Δ
 8 weeks, p = 0.0016). E) Cdk6 mRNA levels of c-Jun
Δ/Δ
 cells 2, 4, 6 and 8 weeks 
after p185
BCR-ABL
 transformation were analyzed by q-PCR (n = 3; two tailed: c-Jun
Δ/Δ
 2 weeks vs. c-Jun
Δ/Δ
 6 
weeks, p = 0.0011; c-Jun
Δ/Δ
 2 weeks vs. c-Jun
Δ/Δ
 8 weeks, p = 0.0004). The fold change compared to c-Jun
Δ/Δ
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Figure 5 
Figure 5: Methylation pattern in the 5’ region of Cdk6 in c-Jun
Δ/Δ
 cells.A) CpG island search and location 
of MSP primers in the Cdk6 5’ region. A 1000 bp fragment which includes the transcription start site of 
Cdk6 was analyzed for the presence of a CpG island using the MethPrimer program 
50
. Blue boxes indicate 
the presence of a CpG island, CpG sites are shown as orange vertical bars. MSP primer binding sites are 
shown as arrows. AP-1 binding sites are shown as black horizontal bars B) Hypermethylation in c-Jun
fl/fl
 
and c-Jun
Δ/Δ
 cells after 2, 4, 6 and 8 weeks of p185
BCR-ABL
 transformation (upper panel) and in stable c-
Jun
fl/fl
 and c-Jun
Δ/Δ
 cell lines (lower panel). A visible PCR product indicates the presence of methylated 
alleles. Abbreviations: H.M., bone marrow of a healthy mou se; +Ctrl (control for methylated samples); -
Ctrl (control for unmethylated samples). C) Bisulphite sequencing of the Cdk6 5’ region of c-Jun
fl/fl 
(upper 
panel) and c-Jun
Δ/Δ 
(lower panel) leukemic cells. The bisulphite sequence allows a positive display of 5-
methyl cytosines in the gene promoter as unmethylated cytosines appear as thymines, while 5-
methylcytosines appear as cytosines in the final sequence. One representive set of data is depicted.  D) 
Immunoblot for c-JUN and CDK6 of c-Jun
Δ/Δ 
and
 
c-Jun
fl/fl 
cells after 12, 24, 36 and 48 hours of Aza-dC 
treatment. β-ACTIN served as loading control. One representative set of data is depicted.E) Percentage of 
living cells 12, 36, 60 and 84 hours after Aza-dC treatment of c-Jun
Δ/Δ 
and
 
c-Jun
fl/fl 
leukemic cells. Viability 
was analyzed by PI-staining. F) Dnmt1, Dnmt3a and Dnmt3b mRNA levels of c-Jun
fl/fl
 and c-Jun
Δ/Δ 
cells were 
analyzed by RT-PCR (n = 3; two tailed; Dnmt3b: p = 0.016). The fold change compared to c-Jun
fl/fl
 mRNA 
levels is shown. Results were normalized by comparison to their Gapdh mRNA expression. 
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Figure 6 
 
Figure 6: CDK6 advances p185
BCR-ABL 
induced leukemia. A) Percentages of B-cells of Fraction A-C in bone 
marrows (left panel) and Fraction D-F in spleens (right panel) of Cdk6
-/-
 mice compared to Cdk6
+/+
 mice 
were analyzed by FACS (n = 3; fraction A: two-tailed; p = 0.0379).  B) [
3
H]-thymidine incorporation into 
fetal liver-derived Cdk6
+/+
 and Cdk6
-/-
 p185
BCR-ABL
-transformed cell lines was measured (n = 6; two-tailed; p 
< 0.0001). C) 1 x 10
5
 cells of p185
BCR-ABL
-transformed Cdk6
+/+ 
(n = 3) and Cdk6
-/-
 (n = 3) were plated and total 
cell numbers were determined after 48, 96 and 144 hours.D) Injection of Cdk6
+/+
 (n = 7), Cdk6
+/- 
(n = 23) 
and Cdk6
-/-
 (n = 16) newborn mice with a replication-deficient Ab-MuLV encoding retrovirus resulted in B-
lymphoid leukemia/lymphoma (mean survival 63 vs. 62 vs. 120 days in Cdk6
+/+
, Cdk6
+/-
 and Cdk6
-/-
 mice, 
respectively; p < 0.0001 for Cdk6
+/+ 
vs. Cdk6
-/-
). E) The infiltration rates of CD19
+
/CD43
+
 cells in the spleens 
of diseased mice were analyzed by FACS (n = 6; two-tailed; p = 0.103).  
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Figure 7 
Figure 7: Re-expression of CDK6 in c-Jun
Δ/Δ 
cells rescues the proliferative defect. A) Immunoblot analysis 
of the enforced expression of CDK6 with a pMSCV-Cdk6-puro retrovirus in c-Jun
Δ/Δ 
cells. β-ACTIN served as 
loading control. B) [
3
H]-thymidine incorporation in c-Jun
fl/fl
, c-Jun
Δ/Δ-puro 
and c-Jun
Δ/Δ-Cdk6-puro 
cell lines (n = 3; 
two-tailed; c-Jun
fl/fl 
vs. c-Jun
Δ/Δ-puro
 p = 0.0053; c-Jun
Δ/Δ-puro 
vs. c-Jun
Δ/Δ-Cdk6-puro
 p = 0.0029) C) Cell cycle 
profiles of c-Jun
fl/fl 
(n = 5) and c-Jun
Δ/Δ-Cdk6-puro
 (n =4) cells, gated on living cells. One representative set of 
data is depicted. D) 1 x 10
6
 c-Jun
fl/fl
, c-Jun
Δ/Δ-puro 
and c-Jun
Δ/Δ-Cdk6-puro 
p185
BCR-ABL
-transformed cells were 
injected subcutaneously into Nu/Nu mice. 2 independent cell lines per each cell type were injected into 
mice (two-tailed; c-Jun
fl/fl 
(n = 17) vs. c-Jun
Δ/Δ-puro
 (n = 17) p < 0.0001; c-Jun
Δ/Δ-puro 
(n = 17) vs. c-Jun
Δ/Δ-Cdk6-puro
 
(n = 11) p = 0.0017). 
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3.5 Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-
mediated tumor surveillance. 
 
Published in Blood. 2008 Dec 1;112(12):4655-64. Epub 2008 Aug 6. 
 
I contributed to this project by generating NK cell cultures, by performing Western Blots, and by 
helping with the in vivo experiments. 
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4 
CONCLUSIONS 
NK cells present a lymphoid subset of immune cells mediating innate immunity. Moreover, NK 
cells shape and modulate the outcome of the adaptive immune response by producing cytokines 
such as IFN-γ and TNF-α. Recent evidence revealed that NK cells possess features of the adaptive 
immune system, including learning and memory (1). This functional pleiotropy led to the concept 
of distinct NK cell subsets with defined roles where diverse effector functions are achieved 
through NK cell diversification (2). 
During the last decade, most studies concentrated on disclosing the mechanism of target cell 
recognition and described signaling pathways leading to NK cell effector functions. The complex 
process of NK cell differentiation occurring at various distinct tissue sites remains largely 
unknown as well as the transcriptional machinery behind. Several transcription factors have 
been implicated in NK cell development, particularly from the iNK cell stage on. Very recently, 
E4BP4 has been identified as key transcription factor that is selectively and critically required for 
early NK cell development (3). Transcription factors control cytokine responsiveness of NK cell 
precursors. Thereby, the cytokine IL-15 plays a crucial role in NK cell development even though 
the detailed mechanism by which IL-15 operates has not been elucidated.  
Until now, one important limitation to study the role of transcription factors in NK cell biology 
has been the lack of a NK cell specific Cre line. The loxP Cre system is widely used to overcome 
the problems of a straight knock out mouse that often results in a severe phenotype, which 
precludes assigning the function of a target protein to a certain cell type.  
The main project of my PhD study (see section 3.1), was to generate a novel mouse line that 
expresses the Cre recombinase under the control of the Ncr1 promotor. This mouse line 
expresses the Cre recombinase exclusively in NK cells without affecting other lymphoid cells and 
allowed me to define the essential role of the transcription factor STAT5 for NK cells 
development and viability. 
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The transcription factor STAT5, activated by IL-2, IL-7 and IL-15, is an important regulator of B 
and T cell development (4-6). I could show that deletion of STAT5 in NK cells impaired NK cell 
development in the bone marrow. Any toxic effects of the Cre recombinase expression per se 
was ruled out since I performed a comprehensive analysis of NK cell development and effector 
functions of Ncr1iCre mice in vitro as well as in vivo. Whereas Ncr1iCre mice showed an unaltered 
NK cell development and function, I demonstrated a severe reduction of NK cells in the 
periphery of Stat5f/f Ncr1iCre mice. NCR1 becomes expressed at the iNK cell stage in the bone 
marrow. Ncr1 induced expression of Cre recombinase and subsequent deletion of Stat5 
coincides with the disappearance of developing NK cells. At the iNK cell stage, the precursor cells 
in the bone marrow become greatly reduced in number. Real time PCR verified that the few NK 
cells remaining in the periphery embody escapers since they show unaltered Stat5 mRNA levels. 
This data suggests that STAT5 is absolutely required for NK cell survival. Moreover, I infected 
purified splenic NK cells with an adenovirus encoding for the Cre recombinase thereby deleting 
Stat5 in vitro. Again, the deletion of Stat5 led to the disappearance of NK cells confirming my 
observation in vivo. The fact that STAT5 regulates antiapoptotic genes such as Bcl-xL and Bcl-2 in 
B and T cells supports the theory of STAT5 being a critical survival factor for NK cells. However, I 
observed an accumulation of NKPs in the bone marrow of Stat5f/f Ncr1iCre mice. This is in line 
with the more immature NK cell phenotype observed in the remaining bone marrow NKs. These 
data suggest an additional role for STAT5, since the accumulation alludes to a developmental 
block at the NKP stage and indicates an important role for STAT5 in the transition to the iNK cell 
stage. For this transition, STAT5 might thereby be downstream of IL-15, which has been shown 
to be an essential fuel driving the differentiation from NKPs to the iNK cell stage. STAT5 may 
regulate either directly or indirectly E4BP4 determining the fate of NKPs in the bone marrow. 
Further studies are required to unravel the transcriptional network regulating NK cell 
differentiation. 
The importance of NK cells in tumor surveillance has been previously shown in vitro as well as in 
vivo (7, 8). In a model using a B16F10 melanoma cell line, which is cleared by NK cells, I failed to 
observe functional NK cells in Stat5f/f Ncr1iCre mice, as expected considering my previous data. 
The severe reduction of NK cells, however, did not impact on the tumor surveillance of an 
adenomacarcinoma cell line called MC38 which is mediated by CD8+ T cells. Therefore, in this 
experimental setting, the absence of NK cells did not impair the adaptive arm of the immune 
system. It has been shown that STAT5 is essential for leukemic initiation and maintenance (9, 
10). STAT5 might therefore be an attractive therapeutic target. However, the inhibition of STAT5 
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would be associated with a strong decrease in NK cell numbers and a severe reduction of NK cell 
mediated tumors. It will therefore be of great importance to evaluate which malignant diseases 
are subjected to NK cell mediated tumor surveillance.  
During my PhD studies, I also contributed to a study investigating the roles of TRAIL and NK cells 
in tumor surveillance against ovarian cancer (see section 3.2). Activated NK cells express tumor 
necrosis factor related apoptosis inducing ligand (TRAIL) that recognizes TRAIL receptors on the 
target membrane (e.g. of a transformed cell) and induces apoptotic cell death. We could show 
that the combination of AD5-10 (TRAIL2 agonistic antibody) and carboplatin (a chemotherapy 
drug) induced an additive antitumor activity. Moreover, we demonstrated that depletion of NK 
cells from mice bearing tumors resulted in increased tumor growth and abolished the cytotoxic 
effect of AD5-10 (11). In summary, the data obtained in this study demonstrates an important 
role for NK cell mediated immunosurveillance in ovarian cancer by using death domain receptor 
mediated apoptosis. Therefore, the administration of STAT5 inhibitors would have negative 
consequences for the host NK cell mediated immunosurveillance in ovarian cancer.  
Another study, to which I contributed, investigated the role of NK cells in leukemogenesis (see 
section 3.5). It has previously been shown that leukemia surveillance is at least partially 
mediated by NK cells (12, 13). We demonstrated that the intracellular signal transducer enzyme 
called phosphoinositide 3-kinase δ (PI3Kδ) is involved in Abelson induced leukemia since the 
presence of PI3Kδ accelerated leukemia progression in vivo. We also discovered that PI3Kδ in NK 
cells is required for efficient degranulation of NK cells and thereby NK cell mediated leukemia 
surveillance. Transplantation studies revealed that PI3Kδ-/- mice succumbed more rapidly to 
cancer and are tumor prone. This study demonstrates a dual role of PI3Kδ in Abelson induced 
leukemia progression that should be taken into consideration when developing a PI3Kδ inhibitor 
as therapeutic strategy. Firstly, disease progression is inhibited upon PI3Kδ deficiency by a tumor 
cell intrinisic effect. Secondly, lack of PI3Kδ leads to impaired NK cell function and therefore to a 
higher tumor susceptibility. 
AS NK cells are capable to recognize and eradicate some types of leukemia and solid tumors very 
efficiently it will be of major importance to evaluate which malignant diseases are cleared by NK 
cells and which molecular inhibitor should be applied to use the therapeutic potential of NK 
cells. 
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